| 产品分类 |
货号 |
产品名称 |
靶点 |
目录价
100μg |
目录价
1mg |
| 单抗 |
CHA500 |
Anti-158P1D7 Reference Antibody (Agensys patent anti-158P1D7) |
158P1D7 |
600 |
2490 |
| 单抗 |
CHB220 |
Anti-AA2AR / Adenosine A2aR Reference Antibody (3F6-9G5) |
A2AR / AA2AR / ADORA2A / ADORA2 |
600 |
2490 |
| 单抗 |
CHA644 |
Anti-ABCB5 Reference Antibody (Brigham and Women's patent anti-ABCB5) |
ABCB5 |
600 |
2490 |
| 单抗 |
COA001 |
Anti-Abm Reference Antibody ( IgG1+Kappa Isotype Control) |
Abm |
600 |
2490 |
| 单抗 |
COA002 |
Anti-Abm Reference Antibody ( IgG4+Kappa Isotype Control) |
Abm |
600 |
2490 |
| 单抗 |
CHA105 |
Anti-ACVR1 / ALK-2 Reference Antibody (DS-6016a) |
ACVR1 / ALK-2 |
600 |
2490 |
| 单抗 |
CHA106 |
Anti-ACVR2A Reference Antibody (Ab-14E1) |
ACVR2A |
600 |
2490 |
| 单抗 |
CHA108 |
Anti-ACVR2B Reference Antibody (bimagrumab) |
ACVR2B |
600 |
2490 |
| 单抗 |
CHA589 |
Anti-ACVR2B Reference Antibody (Acceleron patent anti-ActRIIB) |
ACVR2B |
600 |
2490 |
| 单抗 |
CHB362 |
Anti-ADAM9 Reference Antibody (Imgc936) |
ADAM9 |
600 |
2490 |
| 单抗 |
CHA402 |
Anti-Adrenomedullin Reference Antibody (enibarcimab) |
Adrenomedullin |
600 |
2490 |
| 单抗 |
CHA329 |
Anti-AGER / RAGE Reference Antibody (XT-M4) |
AGER / RAGE |
600 |
2490 |
| 单抗 |
CHA458 |
Anti-Albumin Reference Antibody (Numab patent anti-HSA) |
Albumin |
600 |
2490 |
| 单抗 |
CHA109 |
Anti-ALCAM / CD166 Reference Antibody (praluzatamab) |
ALCAM / CD166 |
600 |
2490 |
| 单抗 |
CHA110 |
Anti-ALCAM / CD166 Reference Antibody (AT002) |
ALCAM / CD166 |
600 |
2490 |
| 单抗 |
CHB355 |
Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp) |
ALP |
600 |
2490 |
| 单抗 |
CHA112 |
Anti-Alpha-synuclein Reference Antibody (cinpanemab) |
Alpha-synuclein |
600 |
2490 |
| 单抗 |
CHA113 |
Anti-Alpha-synuclein Reference Antibody (prasinezumab) |
Alpha-synuclein |
600 |
2490 |
| 单抗 |
CHA371 |
Anti-AMHR2 Reference Antibody (murlentamab) |
AMHR2 |
600 |
2490 |
| 单抗 |
CHA582 |
Anti-Amyloid Alpha Reference Antibody (birtamimab) |
Amyloid Alpha |
600 |
2490 |
| 单抗 |
CHA583 |
Anti-Amyloid Beta Reference Antibody (aducanumab) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA587 |
Anti-Amyloid Beta Reference Antibody (crenezumab) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA588 |
Anti-Amyloid Beta Reference Antibody (DLX212) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA590 |
Anti-Amyloid Beta Reference Antibody (gantenerumab) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA592 |
Anti-Amyloid Beta Reference Antibody (GSK 933776) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA597 |
Anti-Amyloid Beta Reference Antibody (Amgen patent anti-beta amyloid) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA662 |
Anti-Amyloid Beta Reference Antibody (CNTO 2125) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA720 |
Anti-Amyloid Beta Reference Antibody (donanemab) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA805 |
Anti-Amyloid Beta Reference Antibody (Georgetown U. patent anti-Amyloid Beta) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA865 |
Anti-Amyloid Beta Reference Antibody (Kumamoto U. patent anti-Amyloid Beta) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA885 |
Anti-Amyloid Beta Reference Antibody (Merck anti-Amyloid beta 19.3) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHB079 |
Anti-Amyloid Beta Reference Antibody (Rockefeller U. patent anti-Amyloid Beta) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHB107 |
Anti-Amyloid Beta Reference Antibody (solanezumab) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHB153 |
Anti-Amyloid Beta Reference Antibody (U.Illinois scFv59) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHB170 |
Anti-Amyloid Beta Reference Antibody (U.Zurich patent anti-Amyloid Beta) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHB201 |
Anti-Amyloid Beta Reference Antibody (bapineuzumab) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHB202 |
Anti-Amyloid Beta Reference Antibody (lecanemab) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHB690 |
Anti-Amyloid Beta Reference Antibody (Aβab001) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHB691 |
Anti-Amyloid Beta Reference Antibody (Aβab002) |
Amyloid Beta |
600 |
2490 |
| 单抗 |
CHA115 |
Anti-ANGPT2 Reference Antibody (nesvacumab) |
ANGPT2 |
600 |
2490 |
| 单抗 |
CHA600 |
Anti-ANGPT2 Reference Antibody (MEDI3617) |
ANGPT2 |
600 |
2490 |
| 单抗 |
CHA602 |
Anti-ANGPT2 Reference Antibody (zansecimab) |
ANGPT2 |
600 |
2490 |
| 单抗 |
CHA116 |
Anti-ANGPTL3 Reference Antibody (evinacumab) |
ANGPTL3 |
600 |
2490 |
| 单抗 |
CHA604 |
Anti-ANGPTL4 Reference Antibody (Nanyang Tech.U. patent anti-ANGPTL4) |
ANGPTL4 |
600 |
2490 |
| 单抗 |
CHA473 |
Anti-ANGPTL8 Reference Antibody (Regeneron patent anti-ANGPTL8) |
ANGPTL8 |
600 |
2490 |
| 单抗 |
CHA462 |
Anti-ANO1 / TMEM16A Reference Antibody (Novartis patent anti-TMEM16A ) |
ANO1 / TMEM16A |
600 |
2490 |
| 单抗 |
CHA358 |
Anti-AOC3 / VAP1 Reference Antibody (timolumab) |
AOC3 / VAP1 |
600 |
2490 |
| 单抗 |
CHB048 |
Anti-ASIC1 Reference Antibody (Regeneron patent anti-ASIC1) |
ASIC1 |
600 |
2490 |
| 单抗 |
CHA610 |
Anti-AXL / UFO Reference Antibody (tilvestamab) |
AXL / UFO |
600 |
2490 |
| 单抗 |
CHA744 |
Anti-AXL / UFO Reference Antibody (enapotamab) |
AXL / UFO |
600 |
2490 |
| 单抗 |
CHB005 |
Anti-AXL / UFO Reference Antibody (ORY012) |
AXL / UFO |
600 |
2490 |
| 单抗 |
CHA081 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA082 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (MDX-1105) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA083 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA084 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (durvalumab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA611 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (adebrelimab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA614 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (garivulimab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA616 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (manelimab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA618 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (pacmilimab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA619 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (sudubrilimab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA620 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (sugemalimab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA685 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (cosibelimab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA870 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (lodapolimab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA997 |
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (opucolimab) |
B7-H1 / PD-L1 / CD274 |
600 |
2490 |
| 单抗 |
CHA621 |
Anti-B7-H2 / ICOSL / CD275 Reference Antibody (prezalumab) |
B7-H2 / ICOSL / CD275 |
600 |
2490 |
| 单抗 |
CHA119 |
Anti-B7-H3 / CD276 Reference Antibody (enoblituzumab) |
B7-H3 / CD276 |
600 |
2490 |
| 单抗 |
CHA626 |
Anti-B7-H3 / CD276 Reference Antibody (Trellis patent anti-B7-H3) |
B7-H3 / CD276 |
600 |
2490 |
| 单抗 |
CHA887 |
Anti-B7-H3 / CD276 Reference Antibody (mirzotamab) |
B7-H3 / CD276 |
600 |
2490 |
| 单抗 |
CHA978 |
Anti-B7-H3 / CD276 Reference Antibody (omburtamab) |
B7-H3 / CD276 |
600 |
2490 |
| 单抗 |
CHA627 |
Anti-B7-H4 / VTCN1 Reference Antibody (alsevalimab) |
B7-H4 / VTCN1 |
600 |
2490 |
| 单抗 |
CHA628 |
Anti-B7-H4 / VTCN1 Reference Antibody (Millennium patent anti-B7-H4) |
B7-H4 / VTCN1 |
600 |
2490 |
| 单抗 |
CHA120 |
Anti-B7-H5 / VISTA Reference Antibody (onvatilimab) |
B7-H5 / VISTA |
600 |
2490 |
| 单抗 |
CHA121 |
Anti-B7-H6 / NCR3LG1 Reference Antibody (Dartmouth patent anti-B7-H6) |
B7-H6 / NCR3LG1 |
600 |
2490 |
| 单抗 |
CHA629 |
Anti-BACE1 Reference Antibody (Genentech anti-BACE1) |
BACE1 |
600 |
2490 |
| 单抗 |
CHA124 |
Anti-Bcl-2 Reference Antibody (U.Toronto patent anti-Bax) |
Bcl-2 |
600 |
2490 |
| 单抗 |
CHA651 |
Anti-EMMPRIN / CD147 Reference Antibody (Centocor patent anti-CD147) |
BSG2 / CD147 / EMMPRIN |
600 |
2490 |
| 单抗 |
CHA128 |
Anti-BST2 / CD317 Reference Antibody (XmAb 5592) |
BST2 / CD317 |
600 |
2490 |
| 单抗 |
CHB092 |
Anti-BST2 / CD317 Reference Antibody (SBI Biotech patent anti-BST2) |
BST2 / CD317 |
600 |
2490 |
| 单抗 |
CHA832 |
Anti-BTLA / CD272 Reference Antibody (icatolimab) |
BTLA / CD272 |
600 |
2490 |
| 单抗 |
CHA388 |
Anti-BTN3A1 Reference Antibody (CTX-2026) |
BTN3A1 / BTF5 / CD277 |
600 |
2490 |
| 单抗 |
CHB221 |
Anti-BTN3A1 Reference Antibody (ICT-01) |
BTN3A1 / BTF5 / CD277 |
600 |
2490 |
| 单抗 |
CHB222 |
Anti-BTN3A1 Reference Antibody (ICT-01-N297A) |
BTN3A1 / BTF5 / CD277 |
600 |
2490 |
| 单抗 |
CHA403 |
Anti-C1q Reference Antibody (ANX005) |
C1q |
600 |
2490 |
| 单抗 |
CHA129 |
Anti-C1s Reference Antibody (sutimlimab) |
C1s |
600 |
2490 |
| 单抗 |
CHA304 |
Anti-MUC16 Reference Antibody (oregovomab) |
CA125 / MUC16 |
600 |
2490 |
| 单抗 |
CHA581 |
Anti-MUC16 Reference Antibody (abagovomab) |
CA125 / MUC16 |
600 |
2490 |
| 单抗 |
CHA134 |
Anti-CA9 / CAIX Reference Antibody (girentuximab) |
CA9 / Carbonic anhydrase 9 |
600 |
2490 |
| 单抗 |
CHA638 |
Anti-CALCA / CGRP Reference Antibody (eptinezumab) |
CALCA / CGRP |
600 |
2490 |
| 单抗 |
CHA640 |
Anti-CALCA / CGRP Reference Antibody (fremanezumab) |
CALCA / CGRP |
600 |
2490 |
| 单抗 |
CHA642 |
Anti-CALCA / CGRP Reference Antibody (galcanezumab) |
CALCA / CGRP |
600 |
2490 |
| 单抗 |
CHA379 |
Anti-CALCRL / CGRPR Reference Antibody (erenumab) |
CALCRL / CALRL / CGRPR |
600 |
2490 |
| 单抗 |
CHB144 |
Anti-CAPRIN1 Reference Antibody (Toray patent anti-Caprin-1) |
CAPRIN1 |
600 |
2490 |
| 单抗 |
CHA378 |
Anti-CB1 / CNR1 Reference Antibody (GFB-024) |
CB1 / CNR1 / CNR |
600 |
2490 |
| 单抗 |
CHA645 |
Anti-CB1 / CNR1 Reference Antibody (nimacimab) |
CB1 / CNR1 / CNR |
600 |
2490 |
| 单抗 |
CHA179 |
Anti-CCL20 Reference Antibody (GSK3050002) |
CCL20 |
600 |
2490 |
| 单抗 |
CHA137 |
Anti-CCL5 / RANTES Reference Antibody (VLST-002) |
CCL5 / RANTES |
600 |
2490 |
| 单抗 |
CHA648 |
Anti-CCL5 / RANTES Reference Antibody (NI-0701) |
CCL5 / RANTES |
600 |
2490 |
| 单抗 |
CHA031 |
Anti-CCN2 / CTGF Reference Antibody (pamrevlumab) |
CCN2 / CTGF |
600 |
2490 |
| 单抗 |
CHA138 |
Anti-CCR2 / CD192 Reference Antibody (plozalizumab) |
CCR2 / CD192 |
600 |
2490 |
| 单抗 |
CHA139 |
Anti-CCR4 / CD194 Reference Antibody (mogamulizumab) |
CCR4 / CD194 |
600 |
2490 |
| 单抗 |
CHA570 |
Anti-CCR5 / CD195 Reference Antibody (leronlimab) |
CCR5 / CD195 |
600 |
2490 |
| 单抗 |
CHA140 |
Anti-CCR7 / CD197 Reference Antibody (R707) |
CCR7 / CD197 / CMKBR7 / EBI1 / EVI1 |
600 |
2490 |
| 单抗 |
CHA391 |
Anti-CD14 Reference Antibody (atibuclimab) |
CD14 |
600 |
2490 |
| 单抗 |
CHA650 |
Anti-CD151 Reference Antibody (Pierre Fabre patent anti-CD151) |
CD151 |
600 |
2490 |
| 单抗 |
CHA479 |
Anti-CD163 Reference Antibody (OR2805) |
CD163 |
600 |
2490 |
| 单抗 |
CHA013 |
Anti-CD19 Reference Antibody (inebilizumab) |
CD19 |
600 |
2490 |
| 单抗 |
CHA014 |
Anti-CD19 Reference Antibody (tafasitamab) |
CD19 |
600 |
2490 |
| 单抗 |
CHA653 |
Anti-CD19 Reference Antibody (denintuzumab) |
CD19 |
600 |
2490 |
| 单抗 |
CHA654 |
Anti-CD19 Reference Antibody (Duke U. patent anti-CD19) |
CD19 |
600 |
2490 |
| 单抗 |
CHA668 |
Anti-CD19 Reference Antibody (coltuximab) |
CD19 |
600 |
2490 |
| 单抗 |
CHA841 |
Anti-CD19 Reference Antibody (Immunomedics hA19) |
CD19 |
600 |
2490 |
| 单抗 |
CHA872 |
Anti-CD19 Reference Antibody (Loncastuximab) |
CD19 |
600 |
2490 |
| 单抗 |
CHB213 |
Anti-CD19 Reference Antibody (obexelimab) |
CD19 |
600 |
2490 |
| 单抗 |
CHA659 |
Anti-CD2 Reference Antibody (siplizumab) |
CD2 |
600 |
2490 |
| 单抗 |
CHA015 |
Anti-CD20 Reference Antibody (rituximab) |
CD20 |
600 |
2490 |
| 单抗 |
CHA016 |
Anti-CD20 Reference Antibody (obinutuzumab) |
CD20 |
600 |
2490 |
| 单抗 |
CHA671 |
Anti-CD20 Reference Antibody (ripertamab) |
CD20 |
600 |
2490 |
| 单抗 |
CHA673 |
Anti-CD20 Reference Antibody (TRU-015) |
CD20 |
600 |
2490 |
| 单抗 |
CHA675 |
Anti-CD20 Reference Antibody (ublituximab) |
CD20 |
600 |
2490 |
| 单抗 |
CHA677 |
Anti-CD20 Reference Antibody (veltuzumab) |
CD20 |
600 |
2490 |
| 单抗 |
CHA678 |
Anti-CD20 Reference Antibody (zuberitamab) |
CD20 |
600 |
2490 |
| 单抗 |
CHA710 |
Anti-CD20 Reference Antibody (divozilimab) |
CD20 |
600 |
2490 |
| 单抗 |
CHA951 |
Anti-CD20 Reference Antibody (ocaratuzumab) |
CD20 |
600 |
2490 |
| 单抗 |
CHA953 |
Anti-CD20 Reference Antibody (ocrelizumab) |
CD20 |
600 |
2490 |
| 单抗 |
CHA957 |
Anti-CD20 Reference Antibody (ofatumumab) |
CD20 |
600 |
2490 |
| 单抗 |
CHB053 |
Anti-CD20 Reference Antibody (Regeneron patent anti-CD20) |
CD20 |
600 |
2490 |
| 单抗 |
CHA148 |
Anti-CD200 Reference Antibody (samalizumab) |
CD200 |
600 |
2490 |
| 单抗 |
CHA484 |
Anti-CD28 Reference Antibody (lulizumab) |
CD28 |
600 |
2490 |
| 单抗 |
CHA679 |
Anti-CD28 Reference Antibody (FR104) |
CD28 |
600 |
2490 |
| 单抗 |
CHA680 |
Anti-CD28L / CD80 Reference Antibody (galiximab) |
CD28L / CD80 |
600 |
2490 |
| 单抗 |
CHA697 |
Anti-CD3 Reference Antibody (visilizumab) |
CD3 |
600 |
2490 |
| 单抗 |
CHB010 |
Anti-CD3 Reference Antibody (otelixizumab) |
CD3 |
600 |
2490 |
| 单抗 |
CHA699 |
Anti-CD34 Reference Antibody (ITRI patent anti-CD34) |
CD34 |
600 |
2490 |
| 单抗 |
CHB352 |
Anti-CD36 Reference Antibody (Ona Thera Patent Anti-Cd36) |
CD36 |
600 |
2490 |
| 单抗 |
CHA024 |
Anti-CD38 Reference Antibody (daratumumab) |
CD38 |
600 |
2490 |
| 单抗 |
CHA700 |
Anti-CD38 Reference Antibody (felzartamab) |
CD38 |
600 |
2490 |
| 单抗 |
CHA701 |
Anti-CD38 Reference Antibody (isatuximab) |
CD38 |
600 |
2490 |
| 单抗 |
CHA703 |
Anti-CD38 Reference Antibody (mezagitamab) |
CD38 |
600 |
2490 |
| 单抗 |
CHA553 |
Anti-CD3e Reference Antibody (teplizumab) |
CD3e |
600 |
2490 |
| 单抗 |
CHA785 |
Anti-CD3e Reference Antibody (foralumab) |
CD3e |
600 |
2490 |
| 单抗 |
CHA704 |
Anti-CD4 Reference Antibody (ibalizumab) |
CD4 / LEU3 |
600 |
2490 |
| 单抗 |
CHA706 |
Anti-CD4 Reference Antibody (tregalizumab) |
CD4 / LEU3 |
600 |
2490 |
| 单抗 |
CHA707 |
Anti-CD4 Reference Antibody (TRX1) |
CD4 / LEU3 |
600 |
2490 |
| 单抗 |
CHA511 |
Anti-CD44v6 Reference Antibody (bivatuzumab) |
CD44v6 |
600 |
2490 |
| 单抗 |
CHA163 |
Anti-CD46 Reference Antibody (FOR46) |
CD46 |
600 |
2490 |
| 单抗 |
CHA164 |
Anti-CD47 Reference Antibody (magrolimab) |
CD47 |
600 |
2490 |
| 单抗 |
CHA165 |
Anti-CD47 Reference Antibody (CC-90002) |
CD47 |
600 |
2490 |
| 单抗 |
CHA711 |
Anti-CD47 Reference Antibody (letaplimab) |
CD47 |
600 |
2490 |
| 单抗 |
CHA712 |
Anti-CD47 Reference Antibody (ligufalimab) |
CD47 |
600 |
2490 |
| 单抗 |
CHA714 |
Anti-CD47 Reference Antibody (urabrelimab) |
CD47 |
600 |
2490 |
| 单抗 |
CHA867 |
Anti-CD47 Reference Antibody (lemzoparlimab) |
CD47 |
600 |
2490 |
| 单抗 |
CHA374 |
Anti-CD48 Reference Antibody (Regeneron patent anti-CD48) |
CD48 |
600 |
2490 |
| 单抗 |
CHA025 |
Anti-CD5 Reference Antibody (Magenta patent anti-CD5) |
CD5 |
600 |
2490 |
| 单抗 |
CHA166 |
Anti-CD52 Reference Antibody (alemtuzumab) |
CD52 |
600 |
2490 |
| 单抗 |
CHA717 |
Anti-CD52 Reference Antibody (gatralimab) |
CD52 |
600 |
2490 |
| 单抗 |
CHA551 |
Anti-CD59 Reference Antibody ( Mellitus patent anti-CD59) |
CD59 |
600 |
2490 |
| 单抗 |
CHA718 |
Anti-CD59 Reference Antibody (Quark patent anti-CD59) |
CD59 |
600 |
2490 |
| 单抗 |
CHA368 |
Anti-CD6 Reference Antibody (itolizumab) |
CD6 |
600 |
2490 |
| 单抗 |
CHA168 |
Anti-CD69 Reference Antibody (Genefrontier patent anti-CD69) |
CD69 |
600 |
2490 |
| 单抗 |
CHA026 |
Anti-CD7 Reference Antibody (Persongen patent anti-CD7) |
CD7 |
600 |
2490 |
| 单抗 |
CHA721 |
Anti-CD7 Reference Antibody (grisnilimAb) |
CD7 |
600 |
2490 |
| 单抗 |
CHA421 |
Anti-CD74 Reference Antibody (milatuzumab) |
CD74 |
600 |
2490 |
| 单抗 |
CHA171 |
Anti-CD79b Reference Antibody (polatuzumab) |
CD79b |
600 |
2490 |
| 单抗 |
CHA723 |
Anti-CD79b Reference Antibody (iladatuzumAb) |
CD79b |
600 |
2490 |
| 单抗 |
CHA724 |
Anti-CD83 Reference Antibody (Genentech patent anti-CD83) |
CD83 |
600 |
2490 |
| 单抗 |
CHA725 |
Anti-CD9 Reference Antibody (Genentech patent anti-CD9) |
CD9 |
600 |
2490 |
| 单抗 |
CHB358 |
Anti-CD93 Reference Antibody (Dcby02) |
CD93 |
600 |
2490 |
| 单抗 |
CHA172 |
Anti-CDCP1 / CD318 Reference Antibody (U.California patent anti-CDCP1) |
CDCP1 / CD318 |
600 |
2490 |
| 单抗 |
CHB349 |
Anti-CDCP1 / CD318 Reference Antibody (38 E11) |
CDCP1 / CD318 |
600 |
2490 |
| 单抗 |
CHA726 |
Anti-CDH1 / E-cadherin / CD324 Reference Antibody (Stem Centrx patent anti-Cadherin-1) |
CDH1 / E-cadherin / CD324 |
600 |
2490 |
| 单抗 |
CHA566 |
Anti-CDH11 / Cadherin-11 Reference Antibody (RG6125) |
CDH11 / Cadherin-11 |
600 |
2490 |
| 单抗 |
CHB229 |
Anti-CDH17 / Cadherin-17 Reference Antibody (10C12) |
CDH17 / Cadherin-17 |
600 |
2490 |
| 单抗 |
CHB230 |
Anti-CDH17 / Cadherin-17 Reference Antibody (PTA001_A4) |
CDH17 / Cadherin-17 |
600 |
2490 |
| 单抗 |
CHA727 |
Anti-CDH3 / P-cadherin Reference Antibody (PF-03732010) |
CDH3 / P-cadherin |
600 |
2490 |
| 单抗 |
CHA132 |
Anti-CDH6 / K-Cadherin Reference Antibody (HKT288) |
CDH6 / K-Cadherin |
600 |
2490 |
| 单抗 |
CHA364 |
Anti-CDH6 / K-Cadherin Reference Antibody (DS-6000a) |
CDH6 / K-Cadherin |
600 |
2490 |
| 单抗 |
CHA591 |
Anti-Cdiff Toxin A Reference Antibody (actoxumab) |
Cdiff Toxin A |
600 |
2490 |
| 单抗 |
CHA175 |
Anti-CEACAM1 / CD66a Reference Antibody (CM-24) |
CEACAM1 / CD66a |
600 |
2490 |
| 单抗 |
CHA730 |
Anti-CEACAM1 / CD66a Reference Antibody (Chaim Sheba Med. Cntr. patent anti-CEACAM1) |
CEACAM1 / CD66a |
600 |
2490 |
| 单抗 |
CHA174 |
Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab) |
CEACAM5 / CEA / CD66e |
600 |
2490 |
| 单抗 |
CHA731 |
Anti-CEACAM5 / CEA / CD66e Reference Antibody (cergutuzumAb) |
CEACAM5 / CEA / CD66e |
600 |
2490 |
| 单抗 |
CHA735 |
Anti-CEACAM5 / CEA / CD66e Reference Antibody (Tusamitamab) |
CEACAM5 / CEA / CD66e |
600 |
2490 |
| 单抗 |
CHB209 |
Anti-CEACAM5 / CEA / CD66e Reference Antibody (Immunomedics patent anti-CEACAM5 (Class III)) |
CEACAM5 / CEA / CD66e |
600 |
2490 |
| 单抗 |
CHA177 |
Anti-CEACAM6 / CD66c Reference Antibody (NEO-201) |
CEACAM6 / CD66c |
600 |
2490 |
| 单抗 |
CHA737 |
Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) |
CEACAM6 / CD66c |
600 |
2490 |
| 单抗 |
CHA178 |
Anti-CHI3L1 Reference Antibody (Brown U. patent anti-CHI3L1) |
CHI3L1 |
600 |
2490 |
| 单抗 |
CHA739 |
Anti-Clathrin Heavy Chain / CHC Reference Antibody (Academia Sinica patent anti-Clathrin Heavy Chain) |
Clathrin Heavy Chain / CHC |
600 |
2490 |
| 单抗 |
CHA181 |
Anti-CLDN18.2 Reference Antibody (zolbetuximab) |
CLDN18.2 |
600 |
2490 |
| 单抗 |
CHA182 |
Anti-CLDN6 Reference Antibody (IMAB027) |
CLDN6 / CLD6 |
600 |
2490 |
| 单抗 |
CHB232 |
Anti-CLDN6 Reference Antibody (DS-9606a) |
CLDN6 / CLD6 |
600 |
2490 |
| 单抗 |
CHB233 |
Anti-CLDN6 Reference Antibody (AE3-20) |
CLDN6 / CLD6 |
600 |
2490 |
| 单抗 |
CHB234 |
Anti-CLDN6 Reference Antibody (64A) |
CLDN6 / CLD6 |
600 |
2490 |
| 单抗 |
CHB235 |
Anti-CLDN6 Reference Antibody (AB3-7) |
CLDN6 / CLD6 |
600 |
2490 |
| 单抗 |
CHB236 |
Anti-CLDN6 Reference Antibody (AB1-11) |
CLDN6 / CLD6 |
600 |
2490 |
| 单抗 |
CHA184 |
Anti-CLEC14A Reference Antibody (Scripps Korea patent anti-CLEC14A) |
CLEC14A |
600 |
2490 |
| 单抗 |
CHA742 |
Anti-CLEC4C Reference Antibody (BIIB059) |
CLEC4C |
600 |
2490 |
| 单抗 |
CHA743 |
Anti-CLEC4C Reference Antibody (LFB patent anti-BDCA-2) |
CLEC4C |
600 |
2490 |
| 单抗 |
CHA196 |
Anti-CLEC7A Reference Antibody (Baylor patent anti-Dectin-1) |
CLEC7A |
600 |
2490 |
| 单抗 |
CHA392 |
Anti-Clusterin Reference Antibody (AB-16B5) |
Clusterin |
600 |
2490 |
| 单抗 |
CHA389 |
Anti-Complement C2 Reference Antibody (ARGX-117) |
Complement C2 |
600 |
2490 |
| 单抗 |
CHA390 |
Anti-Complement C3 Reference Antibody (NGM621) |
Complement C3 |
600 |
2490 |
| 单抗 |
CHA559 |
Anti-Complement C5 Reference Antibody (eculizumab) |
Complement C5 |
600 |
2490 |
| 单抗 |
CHA690 |
Anti-Complement C5 Reference Antibody (crovalimab) |
Complement C5 |
600 |
2490 |
| 单抗 |
CHA745 |
Anti-Complement C5 Reference Antibody (lendalizumab) |
Complement C5 |
600 |
2490 |
| 单抗 |
CHA747 |
Anti-Complement C5 Reference Antibody (ravulizumab) |
Complement C5 |
600 |
2490 |
| 单抗 |
CHB036 |
Anti-Complement C5 Reference Antibody (pozelimab) |
Complement C5 |
600 |
2490 |
| 单抗 |
CHB130 |
Anti-Complement C5 Reference Antibody (tesidolumab) |
Complement C5 |
600 |
2490 |
| 单抗 |
CHB183 |
Anti-Complement C5 Reference Antibody (vilobelimab) |
Complement C5 |
600 |
2490 |
| 单抗 |
CHA130 |
Anti-Complement C5aR1 Reference Antibody (G2_anti-C5aR) |
Complement C5aR1 |
600 |
2490 |
| 单抗 |
CHA606 |
Anti-Complement C5aR1 Reference Antibody (avdoralimab) |
Complement C5aR1 |
600 |
2490 |
| 单抗 |
CHA750 |
Anti-Complement C5aR1 Reference Antibody (G2 patent anti-C5aR) |
Complement C5aR1 |
600 |
2490 |
| 单抗 |
CHA801 |
Anti-Complement Factor B Reference Antibody (Genentech patent anti-Factor B) |
Complement Factor B |
600 |
2490 |
| 单抗 |
CHA752 |
Anti-Complement Factor D Reference Antibody (lampalizumab) |
Complement Factor D |
600 |
2490 |
| 单抗 |
CHA445 |
Anti-Complement Factor P / Properdin Reference Antibody (Novelmed patent anti-Properdin) |
Complement Factor P / Properdin |
600 |
2490 |
| 单抗 |
CHA503 |
Anti-c-RET Reference Antibody (Regeneron patent anti-RET) |
c-RET |
600 |
2490 |
| 单抗 |
CHA186 |
Anti-CRTAM / CD355 Reference Antibody (Oxford Bio patent anti-CRTAM) |
CRTAM / CD355 |
600 |
2490 |
| 单抗 |
CHA072 |
Anti-CSF1 / M-CSF Reference Antibody (lacnotuzumab) |
CSF1 / M-CSF |
600 |
2490 |
| 单抗 |
CHA188 |
Anti-CSF1R / M-CSFR / CD115 Reference Antibody (cabiralizumab) |
CSF1R / M-CSFR / CD115 |
600 |
2490 |
| 单抗 |
CHA756 |
Anti-CSF1R / M-CSFR / CD115 Reference Antibody (emactuzumab) |
CSF1R / M-CSFR / CD115 |
600 |
2490 |
| 单抗 |
CHA757 |
Anti-CSF1R / M-CSFR / CD115 Reference Antibody (LY3022855) |
CSF1R / M-CSFR / CD115 |
600 |
2490 |
| 单抗 |
CHA758 |
Anti-CSF2 / GM-CSF Reference Antibody (gimsilumab) |
CSF2 / GM-CSF |
600 |
2490 |
| 单抗 |
CHA759 |
Anti-CSF2 / GM-CSF Reference Antibody (lenzilumab) |
CSF2 / GM-CSF |
600 |
2490 |
| 单抗 |
CHA760 |
Anti-CSF2 / GM-CSF Reference Antibody (namilumab) |
CSF2 / GM-CSF |
600 |
2490 |
| 单抗 |
CHB011 |
Anti-CSF2 / GM-CSF Reference Antibody (otilimab) |
CSF2 / GM-CSF |
600 |
2490 |
| 单抗 |
CHB031 |
Anti-CSF2 / GM-CSF Reference Antibody (plonmarlimab) |
CSF2 / GM-CSF |
600 |
2490 |
| 单抗 |
CHB132 |
Anti-CSF2 / GM-CSF Reference Antibody (Theraclone patent anti-GM-CSF) |
CSF2 / GM-CSF |
600 |
2490 |
| 单抗 |
CHA232 |
Anti-CSF2Ra / GM-CSFRa / CD116 Reference Antibody (mavrilimumab) |
CSF2Ra / GM-CSFRa / CD116 |
600 |
2490 |
| 单抗 |
CHA404 |
Anti-CSF2Rb / CD131 Reference Antibody (CSL311) |
CSF2Rb / CD131 |
600 |
2490 |
| 单抗 |
CHA394 |
Anti-CSF3 / G-CSF Reference Antibody (CSL324) |
CSF3 / G-CSF |
600 |
2490 |
| 单抗 |
CHA228 |
Anti-CSF3R / G-CSFR Reference Antibody (CSL patent anti-G-CSFR) |
CSF3R / G-CSFR |
600 |
2490 |
| 单抗 |
CHA032 |
Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) |
CTLA-4 / CD152 |
600 |
2490 |
| 单抗 |
CHA768 |
Anti-CTLA-4 / CD152 Reference Antibody (nurulimab) |
CTLA-4 / CD152 |
600 |
2490 |
| 单抗 |
CHA770 |
Anti-CTLA-4 / CD152 Reference Antibody (tremelimumab) |
CTLA-4 / CD152 |
600 |
2490 |
| 单抗 |
CHA772 |
Anti-CTLA-4 / CD152 Reference Antibody (zalifrelimab) |
CTLA-4 / CD152 |
600 |
2490 |
| 单抗 |
CHB041 |
Anti-CTLA-4 / CD152 Reference Antibody (quavonlimab) |
CTLA-4 / CD152 |
600 |
2490 |
| 单抗 |
CHB203 |
Anti-CTLA-4 / CD152 Reference Antibody (Antitope patent anti-CTLA4) |
CTLA-4 / CD152 |
600 |
2490 |
| 单抗 |
CHA136 |
Anti-CTSS / Cathepsin S Reference Antibody (Fsn0503h) |
CTSS / Cathepsin S |
600 |
2490 |
| 单抗 |
CHA033 |
Anti-CX3CL1 / Fractalkine Reference Antibody (quetmolimab) |
CX3CL1 / Fractalkine |
600 |
2490 |
| 单抗 |
CHA190 |
Anti-CXADR Reference Antibody (Med. Bio. Labs patent anti-CXADR) |
CXADR |
600 |
2490 |
| 单抗 |
CHA474 |
Anti-CXC-ELR Reference Antibody (Lilly patent anti-Pan-ELR+) |
CXC-ELR |
600 |
2490 |
| 单抗 |
CHA191 |
Anti-CXCL10 / IP-10 Reference Antibody (eldelumab) |
CXCL10 / IP-10 |
600 |
2490 |
| 单抗 |
CHA781 |
Anti-CXCL10 / IP-10 Reference Antibody (NI-0801) |
CXCL10 / IP-10 |
600 |
2490 |
| 单抗 |
CHA782 |
Anti-CXCL12 / SDF1a Reference Antibody (Genentech anti-CXCL12) |
CXCL12 / SDF1a / SDF1 |
600 |
2490 |
| 单抗 |
CHA456 |
Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) |
CXCL4 / PF4 |
600 |
2490 |
| 单抗 |
CHA280 |
Anti-CXCL8 / IL-8 Reference Antibody (HuMax-IL8) |
CXCL8 / IL-8 |
600 |
2490 |
| 单抗 |
CHA783 |
Anti-CXCL8 / IL-8 Reference Antibody (ABX-IL8) |
CXCL8 / IL-8 |
600 |
2490 |
| 单抗 |
CHA784 |
Anti-CXCL8 / IL-8 Reference Antibody (Genentech patent anti-IL-8) |
CXCL8 / IL-8 |
600 |
2490 |
| 单抗 |
CHA193 |
Anti-CXCL9 Reference Antibody (Novimmune patent anti-CXCL9) |
CXCL9 |
600 |
2490 |
| 单抗 |
CHA431 |
Anti-CXCR3 / GPR9 / CD183 Reference Antibody (Genzyme patent anti-CXCR3) |
CXCR3 / GPR9 / CD183 |
600 |
2490 |
| 单抗 |
CHA034 |
Anti-CXCR4 / CD184 Reference Antibody (ulocuplumab) |
CXCR4 / CD184 |
600 |
2490 |
| 单抗 |
CHA786 |
Anti-CXCR4 / CD184 Reference Antibody (Dana-Farber patent anti-CXCR4) |
CXCR4 / CD184 |
600 |
2490 |
| 单抗 |
CHA194 |
Anti-CXCR5 / CD185 Reference Antibody (SAR113244) |
CXCR5 / CD185 / BLR1 / MDR15 |
600 |
2490 |
| 单抗 |
CHB076 |
Anti-CYR61 / CCN1 Reference Antibody (Roche patent anti-CCN1) |
CYR61 / CCN1 |
600 |
2490 |
| 单抗 |
CHA180 |
Anti-DCBLD2 / ESDN Reference Antibody (FA19-1) |
DCBLD2 / ESDN |
600 |
2490 |
| 单抗 |
CHA195 |
Anti-DC-SIGN / CD209 Reference Antibody (INSERM patent anti-DC-SIGN) |
DC-SIGN / CD209 |
600 |
2490 |
| 单抗 |
CHB160 |
Anti-DCSTAMP Reference Antibody (U.Rochester patent anti-DC-STAMP) |
DCSTAMP |
600 |
2490 |
| 单抗 |
CHA848 |
Anti-DDR1 / CD167a Reference Antibody (Imperial College anti-DDR1) |
DDR1 / CD167a |
600 |
2490 |
| 单抗 |
CHA197 |
Anti-DKK1 Reference Antibody (BHQ-880) |
DKK1 |
600 |
2490 |
| 单抗 |
CHA494 |
Anti-DLK1 Reference Antibody (LIV-1205) |
DLK1 |
600 |
2490 |
| 单抗 |
CHA037 |
Anti-DLL3 Reference Antibody (rovalpituzumab) |
DLL3 |
600 |
2490 |
| 单抗 |
CHA038 |
Anti-DLL3 Reference Antibody (Dragonfly patent anti-DLL3) |
DLL3 |
600 |
2490 |
| 单抗 |
CHA198 |
Anti-DLL4 Reference Antibody (demcizumab) |
DLL4 |
600 |
2490 |
| 单抗 |
CHA199 |
Anti-DLL4 Reference Antibody (navicixizumab) |
DLL4 |
600 |
2490 |
| 单抗 |
CHA749 |
Anti-DLL4 Reference Antibody (enoticumab) |
DLL4 |
600 |
2490 |
| 单抗 |
CHA797 |
Anti-DLL4 Reference Antibody (Smart Targeting patent anti-DLL4) |
DLL4 |
600 |
2490 |
| 单抗 |
CHA510 |
Anti-DPEP3 Reference Antibody (tamrintamab) |
DPEP3 |
600 |
2490 |
| 单抗 |
CHA617 |
Anti-DPP4 / CD26 Reference Antibody (begelomab) |
DPP4 / CD26 |
600 |
2490 |
| 单抗 |
CHA542 |
Anti-DSG3 Reference Antibody (Forerunner patent anti-DSG3) |
DSG3 |
600 |
2490 |
| 单抗 |
CHA501 |
Anti-Dysadherin Reference Antibody (Centrose patent anti-dysadherin) |
Dysadherin |
600 |
2490 |
| 单抗 |
CHA528 |
Anti-EFNA4 Reference Antibody (PF-06647263) |
EFNA4 |
600 |
2490 |
| 单抗 |
CHA373 |
Anti-Endoglin / CD105 Reference Antibody (carotuximab) |
Endoglin / CD105 |
600 |
2490 |
| 单抗 |
CHB344 |
Anti-ENPP3 / CD203c Reference Antibody (Ags-16C3F) |
ENPP3 / CD203c |
600 |
2490 |
| 单抗 |
CHA159 |
Anti-ENTPD1 / CD39 Reference Antibody (TTX-030) |
ENTPD1 / CD39 |
600 |
2490 |
| 单抗 |
CHA203 |
Anti-EpCAM / TROP1 / CD326 Reference Antibody (citatuzumab) |
EpCAM / TROP1 / CD326 |
600 |
2490 |
| 单抗 |
CHA804 |
Anti-EpCAM / TROP1 / CD326 Reference Antibody (adecatumumab) |
EpCAM / TROP1 / CD326 |
600 |
2490 |
| 单抗 |
CHA991 |
Anti-EpCAM / TROP1 / CD326 Reference Antibody (oportuzumab) |
EpCAM / TROP1 / CD326 |
600 |
2490 |
| 单抗 |
CHA043 |
Anti-EphA2 Reference Antibody (MEDI-547) |
EphA2 |
600 |
2490 |
| 单抗 |
CHA044 |
Anti-EphA2 Reference Antibody (Sanofi Aventis patent anti-EphA2) |
EphA2 |
600 |
2490 |
| 单抗 |
CHA833 |
Anti-EphA3 Reference Antibody (ifabotuzumab) |
EphA3 |
600 |
2490 |
| 单抗 |
CHA205 |
Anti-EphB2 Reference Antibody (Genentech patent anti-EphB2) |
EphB2 |
600 |
2490 |
| 单抗 |
CHA206 |
Anti-EphB4 Reference Antibody (Morphosys patent anti-EphB4) |
EphB4 |
600 |
2490 |
| 单抗 |
CHA207 |
Anti-EphB4 Reference Antibody (VasGene patent anti-EphB4) |
EphB4 |
600 |
2490 |
| 单抗 |
CHA210 |
Anti-EPOR Reference Antibody (Abbott patent anti-EPO Receptor) |
EPOR |
600 |
2490 |
| 单抗 |
CHA041 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (cetuximab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA809 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (7A7) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA810 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (Chinese Mil.Med.Sci. patent anti-EGFR) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA811 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (demupitamab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA812 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (depatuxizumab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA813 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (Duke D2C7) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA814 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (imgatuzumab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA815 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (laprituximab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA817 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (matuzumab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA818 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (necitumumab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA825 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (SerclutamAb) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA826 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (Shanghai Cancer Inst patent anti-EGFRvIII) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA829 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (zalutumumab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA876 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (losatuxizumAb) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA888 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (modotuximab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA912 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (nimotuzumab) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHB056 |
Anti-ERBB1 / EGFR / HER1 Reference Antibody (Regeneron patent anti-EGFR) |
ERBB1 / EGFR / HER1 |
600 |
2490 |
| 单抗 |
CHA051 |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (disitamab) |
ERBB2 / HER2 / CD340 |
600 |
2490 |
| 单抗 |
CHA053 |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (trastuzumab) |
ERBB2 / HER2 / CD340 |
600 |
2490 |
| 单抗 |
CHA054 |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (pertuzumab) |
ERBB2 / HER2 / CD340 |
600 |
2490 |
| 单抗 |
CHA684 |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (coprelotamab) |
ERBB2 / HER2 / CD340 |
600 |
2490 |
| 单抗 |
CHA798 |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (gancotamab) |
ERBB2 / HER2 / CD340 |
600 |
2490 |
| 单抗 |
CHA834 |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (Hersintuzumab) |
ERBB2 / HER2 / CD340 |
600 |
2490 |
| 单抗 |
CHA835 |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (margetuximab) |
ERBB2 / HER2 / CD340 |
600 |
2490 |
| 单抗 |
CHA837 |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (timigutuzumab) |
ERBB2 / HER2 / CD340 |
600 |
2490 |
| 单抗 |
CHB204 |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (BioMab patent anti-Her2) |
ERBB2 / HER2 / CD340 |
600 |
2490 |
| 单抗 |
CHA245 |
Anti-ERBB3 / HER3 Reference Antibody (patritumab) |
ERBB3 / HER3 |
600 |
2490 |
| 单抗 |
CHA246 |
Anti-ERBB3 / HER3 Reference Antibody (seribantumab) |
ERBB3 / HER3 |
600 |
2490 |
| 单抗 |
CHA838 |
Anti-ERBB3 / HER3 Reference Antibody (barecetamab) |
ERBB3 / HER3 |
600 |
2490 |
| 单抗 |
CHA839 |
Anti-ERBB3 / HER3 Reference Antibody (lumretuzumab) |
ERBB3 / HER3 |
600 |
2490 |
| 单抗 |
CHA858 |
Anti-ERG Reference Antibody (Jackson Foundation patent anti-ERG) |
ERG |
600 |
2490 |
| 单抗 |
CHA523 |
Anti-ETBR Reference Antibody (DEDN6526A) |
ETBR |
600 |
2490 |
| 单抗 |
CHA843 |
Anti-F11 / Factor XI Reference Antibody (abelacimab) |
F11 / Factor XI |
600 |
2490 |
| 单抗 |
CHB008 |
Anti-F11 / Factor XI Reference Antibody (osocimab) |
F11 / Factor XI |
600 |
2490 |
| 单抗 |
CHA938 |
Anti-F8 / Factor VIII Reference Antibody (Novo Nordisk patent anti-Factor VIII) |
F8 / Factor VIII |
600 |
2490 |
| 单抗 |
CHA426 |
Anti-F9 / Factor IX Reference Antibody (emicizumab) |
F9 / Factor IX |
600 |
2490 |
| 单抗 |
CHA211 |
Anti-FAP Reference Antibody (sibrotuzumab) |
FAP |
600 |
2490 |
| 单抗 |
CHB346 |
Anti-Fc gamma R1 Reference Antibody (Medarex Patent Anti-Fc-Gamma-R1) |
Fc gamma R1 |
600 |
2490 |
| 单抗 |
CHA845 |
Anti-FceR2 / CD23 Reference Antibody (lumiliximab) |
FceR2 / CD23 |
600 |
2490 |
| 单抗 |
CHA157 |
Anti-FcgR2a / CD32a Reference Antibody (VIB9600) |
FcgR2a / CD32a |
600 |
2490 |
| 单抗 |
CHA846 |
Anti- FcRH5 / IRTA2 / CD307e Reference Antibody (DFRF4539A) |
FcRL5 / IRTA2 / CD307e |
600 |
2490 |
| 单抗 |
CHA045 |
Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) |
FcRn (FCGRT & B2M) |
600 |
2490 |
| 单抗 |
CHA612 |
Anti-FcRn (FCGRT & B2M) Reference Antibody (batoclimab) |
FcRn (FCGRT & B2M) |
600 |
2490 |
| 单抗 |
CHA917 |
Anti-FcRn (FCGRT & B2M) Reference Antibody (nipocalimab) |
FcRn (FCGRT & B2M) |
600 |
2490 |
| 单抗 |
CHB003 |
Anti-FcRn (FCGRT & B2M) Reference Antibody (orilanolimab) |
FcRn (FCGRT & B2M) |
600 |
2490 |
| 单抗 |
CHA214 |
Anti-FGF19 Reference Antibody (1A6) |
FGF19 |
600 |
2490 |
| 单抗 |
CHA215 |
Anti-FGF2 Reference Antibody (HuGAL-F2) |
FGF2 |
600 |
2490 |
| 单抗 |
CHA381 |
Anti-FGF23 Reference Antibody (burosumab) |
FGF23 |
600 |
2490 |
| 单抗 |
CHA850 |
Anti-FGFR1 / CD331 Reference Antibody (Lilly patent anti-FGFR-1) |
FGFR1 / CD331 |
600 |
2490 |
| 单抗 |
CHA046 |
Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) |
FGFR2 / CD332 |
600 |
2490 |
| 单抗 |
CHA047 |
Anti-FGFR2 / CD332 Reference Antibody (aprutumab) |
FGFR2 / CD332 |
600 |
2490 |
| 单抗 |
CHA216 |
Anti-FGFR3 / CD333 Reference Antibody (LY3076226) |
FGFR3 / CD333 |
600 |
2490 |
| 单抗 |
CHA217 |
Anti-FGFR3 / CD333 Reference Antibody (vofatamab) |
FGFR3 / CD333 |
600 |
2490 |
| 单抗 |
CHA218 |
Anti-FGFR4 / CD334 Reference Antibody (U3-1784) |
FGFR4 / CD334 |
600 |
2490 |
| 单抗 |
CHA219 |
Anti-Fibronectin Reference Antibody (L19-TNF) |
Fibronectin |
600 |
2490 |
| 单抗 |
CHA852 |
Anti-Fibronectin Reference Antibody (radretumab) |
Fibronectin |
600 |
2490 |
| 单抗 |
CHA221 |
Anti-FLT3 / CD135 Reference Antibody (IMC-EB10) |
FLT3 / CD135 |
600 |
2490 |
| 单抗 |
CHA090 |
Anti-FOLH1 / PSMA Reference Antibody (rosopatamab) |
FOLH1 / PSMA |
600 |
2490 |
| 单抗 |
CHA853 |
Anti-FOLH1 / PSMA Reference Antibody (pelgifatamAb) |
FOLH1 / PSMA |
600 |
2490 |
| 单抗 |
CHA048 |
Anti-FOLR1 / FRA Reference Antibody (farletuzumab) |
FOLR1 / FRA |
600 |
2490 |
| 单抗 |
CHA049 |
Anti-FOLR1 / FRA Reference Antibody (mirvetuximab) |
FOLR1 / FRA |
600 |
2490 |
| 单抗 |
CHA716 |
Anti-FOLR1 / FRA Reference Antibody (Dompe patent anti-FOLR1) |
FOLR1 / FRA |
600 |
2490 |
| 单抗 |
CHA382 |
Anti-Fucosyl GM1 Reference Antibody (BMS-986012) |
Fucosyl GM1 |
600 |
2490 |
| 单抗 |
CHA855 |
Anti-FZD Reference Antibody (vantictumab) |
FZD |
600 |
2490 |
| 单抗 |
CHA366 |
Anti-FZD10 Reference Antibody (tabituximab) |
FZD10 |
600 |
2490 |
| 单抗 |
CHA224 |
Anti-FZD7 Reference Antibody (U.Toronto patent anti-FZD7) |
FZD7 |
600 |
2490 |
| 单抗 |
CHB163 |
Anti-GAD65 Reference Antibody (U.Washington patent anti-GAD65) |
GAD65 |
600 |
2490 |
| 单抗 |
CHA226 |
Anti-GCGR Reference Antibody (crotedumab) |
GCGR / GLR |
600 |
2490 |
| 单抗 |
CHA227 |
Anti-GCGR Reference Antibody (volagidemab) |
GCGR / GLR |
600 |
2490 |
| 单抗 |
CHA860 |
Anti-GD2 Reference Antibody (dinutuximab) |
GD2 |
600 |
2490 |
| 单抗 |
CHA861 |
Anti-GD2 Reference Antibody (EMD 273063) |
GD2 |
600 |
2490 |
| 单抗 |
CHB210 |
Anti-GD2 Reference Antibody (naxitamab) |
GD2 |
600 |
2490 |
| 单抗 |
CHB034 |
Anti-GDF15 / MIC1 Reference Antibody (ponsegromab) |
GDF15 / MIC1 |
600 |
2490 |
| 单抗 |
CHA306 |
Anti-GDF8 / Myostatin Reference Antibody (landogrozumab) |
GDF8 / Myostatin |
600 |
2490 |
| 单抗 |
CHA307 |
Anti-GDF8 / Myostatin Reference Antibody (trevogrumab) |
GDF8 / Myostatin |
600 |
2490 |
| 单抗 |
CHA601 |
Anti-GDF8 / Myostatin Reference Antibody (apitegromab) |
GDF8 / Myostatin |
600 |
2490 |
| 单抗 |
CHA562 |
Anti-GFRA3 Reference Antibody (nadecnemab) |
GFRA3 |
600 |
2490 |
| 单抗 |
CHA405 |
Anti-GFRAL Reference Antibody (NGM120) |
GFRAL |
600 |
2490 |
| 单抗 |
CHA229 |
Anti-GIPR Reference Antibody (Amgen patent anti-GIPR) |
GIPR |
600 |
2490 |
| 单抗 |
CHB206 |
Anti-GLP1R Reference Antibody (Centocor patent anti-GLP-1R) |
GLP1R |
600 |
2490 |
| 单抗 |
CHA439 |
Anti-GOLM1 Reference Antibody (Cureab patent anti-GP73) |
GOLM1 |
600 |
2490 |
| 单抗 |
CHA407 |
Anti-GP6 / Glycoprotein-6 Reference Antibody (glenzocimab) |
GP6 / Glycoprotein-6 |
600 |
2490 |
| 单抗 |
CHA234 |
Anti-GPA33 Reference Antibody (KRN330) |
GPA33 |
600 |
2490 |
| 单抗 |
CHA513 |
Anti-GPC1 / Glypican-1 Reference Antibody (Minomic patent anti-Glypican 1) |
GPC1 / Glypican-1 |
600 |
2490 |
| 单抗 |
CHB361 |
Anti-GPC2 / Glypican 2 Reference Antibody (Nih Patent Anti-Glypican-2) |
GPC2 / Glypican-2 |
600 |
2490 |
| 单抗 |
CHA050 |
Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab) |
GPC3 / Glypican-3 |
600 |
2490 |
| 单抗 |
CHB224 |
Anti-GPC3 / Glypican-3 Reference Antibody (Codrituzumab-MMAE) |
GPC3 / Glypican-3 |
600 |
2490 |
| 单抗 |
CHA235 |
Anti-GPNMB Reference Antibody (glembatumumab) |
GPNMB |
600 |
2490 |
| 单抗 |
CHA395 |
Anti-GPR20 Reference Antibody (DS-6157) |
GPR20 |
600 |
2490 |
| 单抗 |
CHA437 |
Anti-GPR44 / PTGDR2 / CD294 Reference Antibody (KHK patent anti-CRTH2) |
GPR44 / CRTH2 / PTGDR2 / CD294 |
600 |
2490 |
| 单抗 |
CHA236 |
Anti-GPR49 / LGR5 Reference Antibody (BNC101) |
GPR49 / LGR5 |
600 |
2490 |
| 单抗 |
CHA457 |
Anti-GPR73 / PROKR1 Reference Antibody (Regeneron patent anti-PROKR1） |
GPR73 / PROKR1 |
600 |
2490 |
| 单抗 |
CHA239 |
Anti-GREM1 / Gremlin Reference Antibody (UCB patent anti-Gremlin-1) |
GREM1 / Gremlin |
600 |
2490 |
| 单抗 |
CHA440 |
Anti-GREM1 / Gremlin Reference Antibody (Regeneron patent anti-GREM1) |
GREM1 / Gremlin |
600 |
2490 |
| 单抗 |
CHA418 |
Anti-GUCY2C Reference Antibody (indusatumab) |
GUCY2C |
600 |
2490 |
| 单抗 |
CHA242 |
Anti-Haptoglobin Reference Antibody (KHK patent anti-Haptoglobin) |
Haptoglobin |
600 |
2490 |
| 单抗 |
CHA243 |
Anti-HBEGF Reference Antibody (KHK2866) |
HBEGF |
600 |
2490 |
| 单抗 |
CHA244 |
Anti-HBEGF Reference Antibody (U3-1565) |
HBEGF |
600 |
2490 |
| 单抗 |
CVA002 |
Anti-HBsAg Reference Antibody (OST 577) |
HBsAg |
600 |
2490 |
| 单抗 |
CHA877 |
Anti-Hepcidin / HAMP Reference Antibody (Ludwig-Maximilians U. anti_Hepsin) |
Hepcidin / HAMP |
600 |
2490 |
| 单抗 |
CHA878 |
Anti-Hepcidin / HAMP Reference Antibody (LY2787106) |
Hepcidin / HAMP |
600 |
2490 |
| 单抗 |
CHA247 |
Anti-HGF / SF Reference Antibody (ficlatuzumab) |
HGF / SF |
600 |
2490 |
| 单抗 |
CHA248 |
Anti-HGF / SF Reference Antibody (rilotumumab) |
HGF / SF |
600 |
2490 |
| 单抗 |
CHA881 |
Anti-HGF / SF Reference Antibody (TAK-701) |
HGF / SF |
600 |
2490 |
| 单抗 |
CHA450 |
Anti-HGFA Reference Antibody (Genentech patent anti-HGFA ) |
HGFA |
600 |
2490 |
| 单抗 |
CHA028 |
Anti-HGFR / c-Met Reference Antibody (amivantamab) |
HGFR / c-Met |
600 |
2490 |
| 单抗 |
CHA029 |
Anti-HGFR / c-Met Reference Antibody (telisotuzumab) |
HGFR / c-Met |
600 |
2490 |
| 单抗 |
CHA030 |
Anti-HGFR / c-Met Reference Antibody (onartuzumab) |
HGFR / c-Met |
600 |
2490 |
| 单抗 |
CHA249 |
Anti-HGFR / c-Met Reference Antibody (emibetuzumab) |
HGFR / c-Met |
600 |
2490 |
| 单抗 |
CHA864 |
Anti-HGFR / c-Met Reference Antibody (Korea RIBB patent anti-cMet) |
HGFR / c-Met |
600 |
2490 |
| 单抗 |
CHA883 |
Anti-HGFR / c-Met Reference Antibody (Metheresis patent anti-Met) |
HGFR / c-Met |
600 |
2490 |
| 单抗 |
CHA884 |
Anti-HGFR / c-Met Reference Antibody (SAIT301) |
HGFR / c-Met |
600 |
2490 |
| 单抗 |
CHA468 |
Anti-Histone H2B Reference Antibody (Immunomedics patent anti-Histone H2B) |
Histone H2B |
600 |
2490 |
| 单抗 |
CHA469 |
Anti-Histone H3 Reference Antibody (Immunomedics patent anti-Histone H3) |
Histone H3 |
600 |
2490 |
| 单抗 |
CHA470 |
Anti-Histone H4 Reference Antibody (Immunomedics patent anti-Histone H4) |
Histone H4 |
600 |
2490 |
| 单抗 |
CHA534 |
Anti-HLA-DR Reference Antibody (IMMU-114) |
HLA-DR |
600 |
2490 |
| 单抗 |
CHA475 |
Anti-HTRA1 Reference Antibody (FHTR2163) |
HTRA1 |
600 |
2490 |
| 单抗 |
CHA890 |
Anti-ICAM1 / CD54 Reference Antibody (bersanlimab) |
ICAM1 / CD54 |
600 |
2490 |
| 单抗 |
CHA788 |
Anti-ICAM3 / CD50 Reference Antibody (Forerunner patent anti-ICAM-3) |
ICAM3 / CD50 |
600 |
2490 |
| 单抗 |
CHA251 |
Anti-ICOS / CD278 Reference Antibody (vopratelimab) |
ICOS / CD278 |
600 |
2490 |
| 单抗 |
CHA252 |
Anti-ICOS / CD278 Reference Antibody (feladilimab) |
ICOS / CD278 |
600 |
2490 |
| 单抗 |
CHA596 |
Anti-ICOS / CD278 Reference Antibody (alomfilimab) |
ICOS / CD278 |
600 |
2490 |
| 单抗 |
CHA893 |
Anti-ICOS / CD278 Reference Antibody (MEDI-570) |
ICOS / CD278 |
600 |
2490 |
| 单抗 |
CHA253 |
Anti-IDO2 Reference Antibody (LIMR patent anti-IDO2) |
IDO2 |
600 |
2490 |
| 单抗 |
CHA254 |
Anti-IFNa1 Reference Antibody (rontalizumab) |
IFNa1 |
600 |
2490 |
| 单抗 |
CHA255 |
Anti-IFNa1 Reference Antibody (sifalimumab) |
IFNa1 |
600 |
2490 |
| 单抗 |
CHA613 |
Anti-IFNa1 Reference Antibody (Baylor patent anti-IFN alpha) |
IFNa1 |
600 |
2490 |
| 单抗 |
CHA661 |
Anti-IFNa1 Reference Antibody (Chinese CDC patent anti-Interferon Alpha) |
IFNa1 |
600 |
2490 |
| 单抗 |
CHA383 |
Anti-IFNAR1 Reference Antibody (anifrolumab) |
IFNAR1 |
600 |
2490 |
| 单抗 |
CHB212 |
Anti-IFNAR1 Reference Antibody (Medarex patent anti-IFNAR-1) |
IFNAR1 |
600 |
2490 |
| 单抗 |
CHA780 |
Anti-IFNg Reference Antibody (fontolizumab) |
IFNg |
600 |
2490 |
| 单抗 |
CHA899 |
Anti-IFNg Reference Antibody (AMG 811) |
IFNg |
600 |
2490 |
| 单抗 |
CHA900 |
Anti-IFNg Reference Antibody (emapalumab) |
IFNg |
600 |
2490 |
| 单抗 |
CHA902 |
Anti-IgE Reference Antibody (ligelizumab) |
IgE |
600 |
2490 |
| 单抗 |
CHA904 |
Anti-IgE Reference Antibody (talizumab) |
IgE |
600 |
2490 |
| 单抗 |
CHA977 |
Anti-IgE Reference Antibody (omalizumab) |
IgE |
600 |
2490 |
| 单抗 |
CHA256 |
Anti-IGF-1 Reference Antibody (xentuzumab) |
IGF-1 |
600 |
2490 |
| 单抗 |
CHA017 |
Anti-IGF1R / CD221 Reference Antibody (cixutumumab) |
IGF1-R / IGFR1 / CD221 |
600 |
2490 |
| 单抗 |
CHA257 |
Anti-IGF1R / CD221 Reference Antibody (teprotumumab) |
IGF1-R / IGFR1 / CD221 |
600 |
2490 |
| 单抗 |
CHA694 |
Anti-IGF1R / CD221 Reference Antibody (dalotuzumab) |
IGF1-R / IGFR1 / CD221 |
600 |
2490 |
| 单抗 |
CHA847 |
Anti-IGF1R / CD221 Reference Antibody (Immunomedics patent anti-IGF-1R) |
IGF1-R / IGFR1 / CD221 |
600 |
2490 |
| 单抗 |
CHA874 |
Anti-IGF1R / CD221 Reference Antibody (lonigutamab) |
IGF1-R / IGFR1 / CD221 |
600 |
2490 |
| 单抗 |
CHA909 |
Anti-IGF1R / CD221 Reference Antibody (figitumumab) |
IGF1-R / IGFR1 / CD221 |
600 |
2490 |
| 单抗 |
CHA910 |
Anti-IGF1R / CD221 Reference Antibody (ganitumab) |
IGF1-R / IGFR1 / CD221 |
600 |
2490 |
| 单抗 |
CHB073 |
Anti-IGF1R / CD221 Reference Antibody (robatumumab) |
IGF1-R / IGFR1 / CD221 |
600 |
2490 |
| 单抗 |
CHA914 |
Anti-IGF-2 Reference Antibody (DX-2647) |
IGF-2 |
600 |
2490 |
| 单抗 |
CHA915 |
Anti-IL-10 Reference Antibody (BT-063) |
IL-10 |
600 |
2490 |
| 单抗 |
CHA916 |
Anti-IL-12 (IL-12a & IL-12b) Reference Antibody (briakinumab) |
IL-12 |
600 |
2490 |
| 单抗 |
CHA733 |
Anti-IL-12b Reference Antibody (ebdarokimab) |
IL-12b |
600 |
2490 |
| 单抗 |
CHA259 |
Anti-IL-13 Reference Antibody (anrukinzumab) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA539 |
Anti-IL-13 Reference Antibody (tralokinumab) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA664 |
Anti-IL-13 Reference Antibody (CNTO 607) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA919 |
Anti-IL-13 Reference Antibody (abrezekimab) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA921 |
Anti-IL-13 Reference Antibody (cendakimab) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA922 |
Anti-IL-13 Reference Antibody (dectrekumab) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA923 |
Anti-IL-13 Reference Antibody (GSK 679586) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA924 |
Anti-IL-13 Reference Antibody (H2L6) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA925 |
Anti-IL-13 Reference Antibody (IMA-026) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA926 |
Anti-IL-13 Reference Antibody (lebrikizumab) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA927 |
Anti-IL-13 Reference Antibody (M1295) |
IL-13 |
600 |
2490 |
| 单抗 |
CHA413 |
Anti-IL-13Ra1 / CD213a1 Reference Antibody (MK-6105) |
IL-13Ra1 / CD213a1 |
600 |
2490 |
| 单抗 |
CHA260 |
Anti-IL-13Ra2 / CD213a2 Reference Antibody (Wake Forest U. patent anti-IL-13RA2) |
IL-13Ra2 / CD213a2 |
600 |
2490 |
| 单抗 |
CHA930 |
Anti-IL-15 Reference Antibody (DISC0280) |
IL-15 |
600 |
2490 |
| 单抗 |
AHA027 |
Anti-CTLA-8 / IL-17a Antibody (SY18-VHH-11) |
IL-17 / IL-17A / CTLA-8 |
600 |
2490 |
| 单抗 |
CHA536 |
Anti-CTLA-8 / IL-17a Reference Antibody (secukinumab) |
IL-17 / IL-17A / CTLA-8 |
600 |
2490 |
| 单抗 |
CHA773 |
Anti-CTLA-8 / IL-17a Reference Antibody (CAT-2200) |
IL-17 / IL-17A / CTLA-8 |
600 |
2490 |
| 单抗 |
CHA774 |
Anti-CTLA-8 / IL-17a Reference Antibody (ixekizumab) |
IL-17 / IL-17A / CTLA-8 |
600 |
2490 |
| 单抗 |
CHA775 |
Anti-CTLA-8 / IL-17a Reference Antibody (netakimab) |
IL-17 / IL-17A / CTLA-8 |
600 |
2490 |
| 单抗 |
CHA776 |
Anti-CTLA-8 / IL-17a Reference Antibody (perakizumab) |
IL-17 / IL-17A / CTLA-8 |
600 |
2490 |
| 单抗 |
CHA778 |
Anti-CTLA-8 / IL-17a Reference Antibody (UCB patent anti-IL-17) |
IL-17 / IL-17A / CTLA-8 |
600 |
2490 |
| 单抗 |
CHA779 |
Anti-CTLA-8 / IL-17a Reference Antibody (vunakizumab) |
IL-17 / IL-17A / CTLA-8 |
600 |
2490 |
| 单抗 |
CHA057 |
Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) |
IL-17Ra / CD217 |
600 |
2490 |
| 单抗 |
CHA058 |
Anti-IL-18 Reference Antibody (GSK 1070806) |
IL-18 |
600 |
2490 |
| 单抗 |
CHA933 |
Anti-IL-18 Reference Antibody (ABT-325) |
IL-18 |
600 |
2490 |
| 单抗 |
CHA936 |
Anti-IL-1a Reference Antibody (bermekimab) |
IL-1a |
600 |
2490 |
| 单抗 |
CHA483 |
Anti-IL-1b Reference Antibody (canakinumab) |
IL-1b |
600 |
2490 |
| 单抗 |
CHA807 |
Anti-IL-1b Reference Antibody (gevokizumab) |
IL-1b |
600 |
2490 |
| 单抗 |
CHA937 |
Anti-IL-1b Reference Antibody (CDP484) |
IL-1b |
600 |
2490 |
| 单抗 |
CHA262 |
Anti-IL-1R1 / CD121a Reference Antibody (AMG 108) |
IL-1R1 / CD121a |
600 |
2490 |
| 单抗 |
CHA059 |
Anti-IL-1RAP / IL-1R3 Reference Antibody (nidanilimab) |
IL-1RAP / IL-1R3 |
600 |
2490 |
| 单抗 |
CHA605 |
Anti-IL-1RL1 / ST2 / IL-33R Reference Antibody (astegolimab) |
IL-1RL1 / ST2 / IL-33R |
600 |
2490 |
| 单抗 |
CHA939 |
Anti-IL-1RL1 / ST2 / IL-33R Reference Antibody (melrilimab) |
IL-1RL1 / ST2 / IL-33R |
600 |
2490 |
| 单抗 |
CHA263 |
Anti-IL-1RL2 / IL-36R Reference Antibody (spesolimab) |
IL-1RL2 / IL-36R |
600 |
2490 |
| 单抗 |
CHA264 |
Anti-IL-1RL2 / IL-36R Reference Antibody (imsidolimab) |
IL-1RL2 / IL-36R |
600 |
2490 |
| 单抗 |
CHA266 |
Anti-IL-20 Reference Antibody (fletikumab) |
IL-20 |
600 |
2490 |
| 单抗 |
CHA940 |
Anti-IL-20 Reference Antibody (Cheng Kung U. patent anti-IL-20) |
IL-20 |
600 |
2490 |
| 单抗 |
CHA267 |
Anti-IL-20Ra Reference Antibody (Cheng Kung U. patent anti-IL-20R1) |
IL-20Ra |
600 |
2490 |
| 单抗 |
CHA060 |
Anti-IL-21 Reference Antibody (Lilly patent anti-IL-21) |
IL-21 |
600 |
2490 |
| 单抗 |
CHA941 |
Anti-IL-21 Reference Antibody (avizakimab) |
IL-21 |
600 |
2490 |
| 单抗 |
CHA268 |
Anti-IL-22 Reference Antibody (fezakinumab) |
IL-22 |
600 |
2490 |
| 单抗 |
CHA384 |
Anti-IL-22Ra Reference Antibody (ARGX-112) |
IL-22Ra |
600 |
2490 |
| 单抗 |
CHA269 |
Anti-IL-23 Reference Antibody (guselkumab) |
IL-23 |
600 |
2490 |
| 单抗 |
CHA942 |
Anti-IL-23 Reference Antibody (brazikumab) |
IL-23 |
600 |
2490 |
| 单抗 |
CHA944 |
Anti-IL-23 Reference Antibody (LY2525623) |
IL-23 |
600 |
2490 |
| 单抗 |
CHA945 |
Anti-IL-23 Reference Antibody (mirikizumab) |
IL-23 |
600 |
2490 |
| 单抗 |
CHA270 |
Anti-IL-23a Reference Antibody (tildrakizumab) |
IL-23a |
600 |
2490 |
| 单抗 |
CHA947 |
Anti-IL-23a Reference Antibody (risankizumab) |
IL-23a |
600 |
2490 |
| 单抗 |
CHA655 |
Anti-IL-25 Reference Antibody (Centocor patent anti-IL-25) |
IL-25 |
600 |
2490 |
| 单抗 |
CHA151 |
Anti-IL-2Ra / CD25 Reference Antibody (basiliximab) |
IL-2Ra / CD25 |
600 |
2490 |
| 单抗 |
CHA272 |
Anti-IL-2Ra / CD25 Reference Antibody (daclizumab) |
IL-2Ra / CD25 |
600 |
2490 |
| 单抗 |
CHA950 |
Anti-IL-2Ra / CD25 Reference Antibody (camidanlumab) |
IL-2Ra / CD25 |
600 |
2490 |
| 单抗 |
CHA271 |
Anti-IL-2Rb / CD122 Reference Antibody (Singapore ASTR patent anti-IL-2R beta / IL-2R gamma ) |
IL-2Rb / CD122 |
600 |
2490 |
| 单抗 |
CHA273 |
Anti-IL-31Ra Reference Antibody (nemolizumab) |
IL-31Ra |
600 |
2490 |
| 单抗 |
CHA274 |
Anti-IL-33 Reference Antibody (etokimab) |
IL-33 |
600 |
2490 |
| 单抗 |
CHA954 |
Anti-IL-33 Reference Antibody (itepekimab) |
IL-33 |
600 |
2490 |
| 单抗 |
CHB148 |
Anti-IL-33 Reference Antibody (torudokimab) |
IL-33 |
600 |
2490 |
| 单抗 |
CHB149 |
Anti-IL-33 Reference Antibody (tozorakimab) |
IL-33 |
600 |
2490 |
| 单抗 |
CHA142 |
Anti-IL-3Ra / CD123 Reference Antibody (SGN-CD123A) |
IL-3Ra / CD123 |
600 |
2490 |
| 单抗 |
CHA143 |
Anti-IL-3Ra / CD123 Reference Antibody (talacotuzumab) |
IL-3Ra / CD123 |
600 |
2490 |
| 单抗 |
CHA275 |
Anti-IL-4 Reference Antibody (pascolizumab) |
IL-4 |
600 |
2490 |
| 单抗 |
CHA276 |
Anti-IL-4Ra / CD124 Reference Antibody (dupilumab) |
IL-4Ra / CD124 |
600 |
2490 |
| 单抗 |
CHA959 |
Anti-IL-4Ra / CD124 Reference Antibody (MEDI2045) |
IL-4Ra / CD124 |
600 |
2490 |
| 单抗 |
CHA277 |
Anti-IL-5 Reference Antibody (mepolizumab) |
IL-5 |
600 |
2490 |
| 单抗 |
CHA708 |
Anti-IL-5 Reference Antibody (depemokimab) |
IL-5 |
600 |
2490 |
| 单抗 |
CHA960 |
Anti-IL-5 Reference Antibody (Abgenix anti-IL-5) |
IL-5 |
600 |
2490 |
| 单抗 |
CHA278 |
Anti-IL-5Ra/ CD125 Reference Antibody (benralizumab) |
IL-5Ra/ CD125 |
600 |
2490 |
| 单抗 |
CHA062 |
Anti-IL-6 / IFNb2 Reference Antibody (clazakizumab) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA740 |
Anti-IL-6 / IFNb2 Reference Antibody (elsilimomab) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA962 |
Anti-IL-6 / IFNb2 Reference Antibody (Chugai SK2) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA963 |
Anti-IL-6 / IFNb2 Reference Antibody (CSTRI patent anti-IL-6) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA965 |
Anti-IL-6 / IFNb2 Reference Antibody (Medarex patent anti-IL-6) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA966 |
Anti-IL-6 / IFNb2 Reference Antibody (MEDI 5117) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA967 |
Anti-IL-6 / IFNb2 Reference Antibody (Merck patent anti-IL-6) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA969 |
Anti-IL-6 / IFNb2 Reference Antibody (siltuximab) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA970 |
Anti-IL-6 / IFNb2 Reference Antibody (sirukumab) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA971 |
Anti-IL-6 / IFNb2 Reference Antibody (ziltivekimab) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA976 |
Anti-IL-6 / IFNb2 Reference Antibody (olokizumab) |
IL-6 / IFNb2 |
600 |
2490 |
| 单抗 |
CHA063 |
Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) |
IL-6Ra / CD126 |
600 |
2490 |
| 单抗 |
CHA064 |
Anti-IL-6Ra / CD126 Reference Antibody (sarilumab) |
IL-6Ra / CD126 |
600 |
2490 |
| 单抗 |
CHA065 |
Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) |
IL-6Ra / CD126 |
600 |
2490 |
| 单抗 |
CHA972 |
Anti-IL-6Ra / CD126 Reference Antibody (APX007) |
IL-6Ra / CD126 |
600 |
2490 |
| 单抗 |
CHA973 |
Anti-IL-6Ra / CD126 Reference Antibody (levilimab) |
IL-6Ra / CD126 |
600 |
2490 |
| 单抗 |
CHA974 |
Anti-IL-6Ra / CD126 Reference Antibody (sapelizumab) |
IL-6Ra / CD126 |
600 |
2490 |
| 单抗 |
CHA279 |
Anti-IL-7Ra / CD127 Reference Antibody (lusvertikimab) |
IL-7Ra / CD127 |
600 |
2490 |
| 单抗 |
CHA979 |
Anti-IL-7Ra / CD127 Reference Antibody (PF-06342674) |
IL-7Ra / CD127 |
600 |
2490 |
| 单抗 |
CHA282 |
Anti-IL-9 Reference Antibody (enokizumab) |
IL-9 |
600 |
2490 |
| 单抗 |
CHA414 |
Anti-ILDR2 Reference Antibody (bapotulimab) |
ILDR2 |
600 |
2490 |
| 单抗 |
CHA401 |
Anti-INHBA / Activin A Reference Antibody (garetosmab) |
INHBA / Activin A |
600 |
2490 |
| 单抗 |
CHB014 |
Anti-INHBB / Activin B Reference Antibody (Oxford Brookes U. patent anti-Activin Beta-B) |
INHBB / Activin B |
600 |
2490 |
| 单抗 |
CHA514 |
Anti-Integrin a11 / ITAG11 Reference Antibody (Scripps patent anti-CD11a) |
Integrin a11 / ITAG11 |
600 |
2490 |
| 单抗 |
CHB112 |
Anti-Integrin a2b3 (ITGA2 & ITGB3) Reference Antibody (tadocizumab) |
Integrin a2b3 (ITGA2 & ITGB3) |
600 |
2490 |
| 单抗 |
CHA578 |
Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody (abrilumab) |
Integrin a4b7 (ITGA4 & ITGB7) |
600 |
2490 |
| 单抗 |
CHA761 |
Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody (etrolizumab) |
Integrin a4b7 (ITGA4 & ITGB7) |
600 |
2490 |
| 单抗 |
CHB178 |
Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody (vedolizumab) |
Integrin a4b7 (ITGA4 & ITGB7) |
600 |
2490 |
| 单抗 |
CHA984 |
Anti-Integrin a5b1 (ITGA5 & ITGB1) Reference Antibody (BMS patent anti-Integrin α5β1) |
Integrin a5b1 (ITGA5 & ITGB1) |
600 |
2490 |
| 单抗 |
CHB188 |
Anti-Integrin a5b1 (ITGA5 & ITGB1) Reference Antibody (volociximab) |
Integrin a5b1 (ITGA5 & ITGB1) |
600 |
2490 |
| 单抗 |
CHA986 |
Anti-Integrin aL / ITGAL / CD11a Reference Antibody (efalizumab) |
Integrin aL / ITGAL / CD11a |
600 |
2490 |
| 单抗 |
CHA987 |
Anti-Integrin aV / ITGAV / CD51 Reference Antibody (abituzumab) |
Integrin aV / ITGAV / CD51 |
600 |
2490 |
| 单抗 |
CHA988 |
Anti-Integrin aV / ITGAV / CD51 Reference Antibody (intetumumab) |
Integrin aV / ITGAV / CD51 |
600 |
2490 |
| 单抗 |
CHA989 |
Anti-Integrin aVb3 (ITGAV & ITGB3) Reference Antibody (etaracizumab) |
Integrin aVb3 |
600 |
2490 |
| 单抗 |
CHA420 |
Anti-Integrin aVb6 (ITGAV & ITGB6) Reference Antibody (STX-100) |
Integrin aVb6 (ITGAV & ITGB6) |
600 |
2490 |
| 单抗 |
CHA396 |
Anti-Integrin b1 / ITGB1 / CD29 Reference Antibody (OS2966) |
Integrin b1 / ITGB1 / CD29 |
600 |
2490 |
| 单抗 |
CHA442 |
Anti-Integrin b2 / ITGB2 / CD18 Reference Antibody (erlizumab) |
Integrin b2 / ITGB2 / CD18 |
600 |
2490 |
| 单抗 |
CHA465 |
Anti-Integrin b7 / ITGB7 Reference Antibody (Genentech patent anti-Integrin β7) |
Integrin b7 / ITGB7 |
600 |
2490 |
| 单抗 |
CHA491 |
Anti-KAAG1 Reference Antibody (ADCT-901) |
KAAG1 |
600 |
2490 |
| 单抗 |
CHB226 |
Anti-KAAG1 Reference Antibody (ADCT-901-MMAE) |
KAAG1 |
600 |
2490 |
| 单抗 |
CHA879 |
Anti-KID3 Reference Antibody (Macrogenics patent anti-KID3) |
KID3 |
600 |
2490 |
| 单抗 |
CHA067 |
Anti-KIR Reference Antibody (lirilumab) |
KIR |
600 |
2490 |
| 单抗 |
CHA283 |
Anti-KIR2DL1 / CD158a Reference Antibody (Innate patent anti-KIR2DL) |
KIR2DL1 / CD158a |
600 |
2490 |
| 单抗 |
CHA068 |
Anti-KIR3DL2 / CD158k Reference Antibody (lacutamab) |
KIR3DL2 / CD158k |
600 |
2490 |
| 单抗 |
CHA546 |
Anti-KLK2 / Kallikrein 2 Reference Antibody (JNJ-69086420) |
KLK2 / Kallikrein 2 |
600 |
2490 |
| 单抗 |
CHA452 |
Anti-KLK5 / Kallikrein 5 Reference Antibody (Genentech patent anti-KLK5) |
KLK5 / Kallikrein 5 |
600 |
2490 |
| 单抗 |
CHA126 |
Anti-Klotho Beta Reference Antibody (RG7992) |
Klotho Beta |
600 |
2490 |
| 单抗 |
CHA127 |
Anti-Klotho Beta Reference Antibody (NGM313) |
Klotho Beta |
600 |
2490 |
| 单抗 |
CHA285 |
Anti-LAG3 / CD223 Reference Antibody (relatlimab) |
LAG3 / CD223 |
600 |
2490 |
| 单抗 |
CHA992 |
Anti-LAG3 / CD223 Reference Antibody (encelimab) |
LAG3 / CD223 |
600 |
2490 |
| 单抗 |
CHA993 |
Anti-LAG3 / CD223 Reference Antibody (favezelimab) |
LAG3 / CD223 |
600 |
2490 |
| 单抗 |
CHA994 |
Anti-LAG3 / CD223 Reference Antibody (fianlimab) |
LAG3 / CD223 |
600 |
2490 |
| 单抗 |
CHA995 |
Anti-LAG3 / CD223 Reference Antibody (ieramilimab) |
LAG3 / CD223 |
600 |
2490 |
| 单抗 |
CHA996 |
Anti-LAG3 / CD223 Reference Antibody (miptenalimab) |
LAG3 / CD223 |
600 |
2490 |
| 单抗 |
CHA527 |
Anti-LAMP1 / CD107a Reference Antibody ( SAR428926) |
LAMP1 / CD107a |
600 |
2490 |
| 单抗 |
CHA286 |
Anti-LAP Reference Antibody (Brigham and Womens anti-LAP) |
LAP |
600 |
2490 |
| 单抗 |
CHA287 |
Anti-LEPR / CD295 Reference Antibody (mibavademab) |
LEPR / CD295 |
600 |
2490 |
| 单抗 |
CHA288 |
Anti-Lewis Y Reference Antibody (MB 311) |
Lewis Y |
600 |
2490 |
| 单抗 |
CHA069 |
Anti-LIF Reference Antibody (MSC-1) |
LIF |
600 |
2490 |
| 单抗 |
CHA289 |
Anti-LILRB2 / ILT4 / CD85d Reference Antibody (JTX-8064) |
LILRB2 / ILT4 / CD85d |
600 |
2490 |
| 单抗 |
CHA070 |
Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex) |
LILRB4 / ILT3 / CD85k |
600 |
2490 |
| 单抗 |
CHA071 |
Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4) |
LILRB4 / ILT3 / CD85k |
600 |
2490 |
| 单抗 |
CHA990 |
Anti-LINGO1 Reference Antibody (opicinumab) |
LINGO1 |
600 |
2490 |
| 单抗 |
CHA999 |
Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab) |
LIV-1 / SLC39A6 |
600 |
2490 |
| 单抗 |
CHA290 |
Anti-LOXL2 Reference Antibody (simtuzumab) |
LOXL2 |
600 |
2490 |
| 单抗 |
CHA524 |
Anti-LRRC15 / LIB Reference Antibody (samrotamab) |
LRRC15 / LIB |
600 |
2490 |
| 单抗 |
CHA486 |
Anti-Ly6E Reference Antibody (RG7841) |
Ly6E |
600 |
2490 |
| 单抗 |
CHA035 |
Anti-LY75 / CD205/DEC-205 Reference Antibody (MEN1309) |
LY75 / CD205 / DEC-205 / CLEC13B |
600 |
2490 |
| 单抗 |
CHA036 |
Anti-LY75 / CD205/DEC-205 Reference Antibody (CDX-1401) |
LY75 / CD205 / DEC-205 / CLEC13B |
600 |
2490 |
| 单抗 |
CHA292 |
Anti-MADCAM1 Reference Antibody (ontamalimab) |
MADCAM1 |
600 |
2490 |
| 单抗 |
CHA294 |
Anti-MAGEA3 Reference Antibody (CT Atlantic patent anti-MAGE-A3) |
MAGEA3 |
600 |
2490 |
| 单抗 |
CHB360 |
Anti-MAGE-A4 Reference Antibody (Imc-C103C) |
MAGE-A4 |
600 |
2490 |
| 单抗 |
CHA296 |
Anti-MASP2 Reference Antibody (narsoplimab) |
MASP2 |
600 |
2490 |
| 单抗 |
CHA497 |
Anti-Matriptase Reference Antibody (Oxford Bio patent anti-Matriptase) |
Matriptase |
600 |
2490 |
| 单抗 |
CHB353 |
Anti-Meflin Reference Antibody (Tokai U. Patent Anti-Meflin) |
Meflin |
600 |
2490 |
| 单抗 |
CHA375 |
Anti-Melanotransferrin / CD228 Reference Antibody (SC-005) |
Melanotransferrin / CD228 |
600 |
2490 |
| 单抗 |
CHA297 |
Anti-MER / MERTK Reference Antibody (RGX-019) |
MER / MERTK |
600 |
2490 |
| 单抗 |
CHA298 |
Anti-Mesothelin Reference Antibody (amatuximab) |
Mesothelin |
600 |
2490 |
| 单抗 |
CHA299 |
Anti-Mesothelin Reference Antibody (anetumab) |
Mesothelin |
600 |
2490 |
| 单抗 |
CHA911 |
Anti-Mesothelin Reference Antibody (NIH patent anti-Mesothelin) |
Mesothelin |
600 |
2490 |
| 单抗 |
CHB007 |
Anti-Mesothelin Reference Antibody (BMS-986148) |
Mesothelin |
600 |
2490 |
| 单抗 |
CHA556 |
Anti-MICA Reference Antibody (CLN-619) |
MICA |
600 |
2490 |
| 单抗 |
CHB164 |
Anti-MICB Reference Antibody (U.Washington patent anti-MICB) |
MICB |
600 |
2490 |
| 单抗 |
CHA300 |
Anti-MIF Reference Antibody (imalumab) |
MIF |
600 |
2490 |
| 单抗 |
CHA301 |
Anti-MMP9 Reference Antibody (andecaliximab) |
MMP9 |
600 |
2490 |
| 单抗 |
CHB009 |
Anti-MMP9 Reference Antibody (Yeda patent anti-MMP-9) |
MMP9 |
600 |
2490 |
| 单抗 |
CHA432 |
Anti-MPL / TPOR / CD110 Reference Antibody (TA136) |
MPL / TPOR / CD110 |
600 |
2490 |
| 单抗 |
CHA498 |
Anti-MRC2 / CD280 Reference Antibody (Copenhagen Rigshospitalet patent anti-uPARAP) |
MRC2 / CD280 |
600 |
2490 |
| 单抗 |
CHB040 |
Anti-MRC2 / CD280 Reference Antibody (Quark patent anti-ENDO 180) |
MRC2 / CD280 |
600 |
2490 |
| 单抗 |
CHB345 |
Anti-MRC2 / CD280 Reference Antibody (Quark Patent Anti-Endo180) |
MRC2 / CD280 |
600 |
2490 |
| 单抗 |
CHA331 |
Anti-MSPR / RON / CD136 Reference Antibody (narnatumab) |
MSPR / RON / CD136 |
600 |
2490 |
| 单抗 |
CHA607 |
Anti-MSPR / RON / CD136 Reference Antibody (Aveo anti-RON) |
MSPR / RON / CD136 |
600 |
2490 |
| 单抗 |
CHB348 |
Anti-MSPR / RON / CD136 Reference Antibody (H5B14) |
MSPR / RON / CD136 |
600 |
2490 |
| 单抗 |
CHA302 |
Anti-MU5AC Reference Antibody (ensituximab) |
MU5AC |
600 |
2490 |
| 单抗 |
CHA303 |
Anti-MUC1 Reference Antibody (clivatuzumab) |
MUC1 |
600 |
2490 |
| 单抗 |
CHA509 |
Anti-MUC1 Reference Antibody (cantuzumab) |
MUC1 |
600 |
2490 |
| 单抗 |
CHA799 |
Anti-MUC1 Reference Antibody (gatipotuzumab) |
MUC1 |
600 |
2490 |
| 单抗 |
CHA789 |
Anti-MUC17 Reference Antibody (Forerunner patent anti-Muc 17) |
MUC17 |
600 |
2490 |
| 单抗 |
CHB015 |
Anti-MUC18 / MCAM / CD146 Reference Antibody (imaprelimab) |
MUC18 / MCAM / CD146 |
600 |
2490 |
| 单抗 |
CHA554 |
Anti-MUSK Reference Antibody (Argenx patent anti-MuSK) |
MUSK |
600 |
2490 |
| 单抗 |
CHB359 |
Anti-NAMPT Reference Antibody (Alt-100) |
NAMPT |
600 |
2490 |
| 单抗 |
CHA422 |
Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) |
NaPi2b / SLC34A2 |
600 |
2490 |
| 单抗 |
CHB106 |
Anti-NaPi2b / SLC34A2 Reference Antibody (upifitamab) |
NaPi2b / SLC34A2 |
600 |
2490 |
| 单抗 |
CHA167 |
Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab) |
NCAM1 / CD56 |
600 |
2490 |
| 单抗 |
CHA073 |
Anti-Nectin-4 Reference Antibody (enfortumab) |
Nectin-4 |
600 |
2490 |
| 单抗 |
CHA308 |
Anti-NGF / bNGF Reference Antibody (fulranumab) |
NGF / bNGF |
600 |
2490 |
| 单抗 |
CHA309 |
Anti-NGF / bNGF Reference Antibody (tanezumab) |
NGF / bNGF |
600 |
2490 |
| 单抗 |
CHB017 |
Anti-NGF / bNGF Reference Antibody (AS2886401-00) |
NGF / bNGF |
600 |
2490 |
| 单抗 |
CHB018 |
Anti-NGF / bNGF Reference Antibody (fasinumab) |
NGF / bNGF |
600 |
2490 |
| 单抗 |
CHB019 |
Anti-NGF / bNGF Reference Antibody (MEDI-578) |
NGF / bNGF |
600 |
2490 |
| 单抗 |
CHA310 |
Anti-NKG2A / CD159a Reference Antibody (monalizumab) |
NKG2A / CD159a |
600 |
2490 |
| 单抗 |
CHA074 |
Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) |
NKG2D / CD314 |
600 |
2490 |
| 单抗 |
CHA443 |
Anti-Nogo Receptor / NgR Reference Antibody (Abbott patent anti-NGR) |
Nogo Receptor / NgR |
600 |
2490 |
| 单抗 |
CHA312 |
Anti-NOTCH1 Reference Antibody (brontictuzumab) |
NOTCH1 |
600 |
2490 |
| 单抗 |
CHB027 |
Anti-NOTCH1 Reference Antibody (Pfizer patent anti-Notch1) |
NOTCH1 |
600 |
2490 |
| 单抗 |
CHA531 |
Anti-NOTCH3 Reference Antibody (tarextumab) |
NOTCH3 |
600 |
2490 |
| 单抗 |
CHA802 |
Anti-NOTCH3 Reference Antibody (Genentech patent anti-Notch3) |
NOTCH3 |
600 |
2490 |
| 单抗 |
CHA313 |
Anti-NRP1 / VEGF165R / CD304 Reference Antibody (vesencumab) |
NRP1 / VEGF165R / CD304 |
600 |
2490 |
| 单抗 |
CHA075 |
Anti-NT5E / CD73 Reference Antibody (oleclumab) |
NT5E / CD73 |
600 |
2490 |
| 单抗 |
CHA903 |
Anti-NT5E / CD73 Reference Antibody (mupadolimab) |
NT5E / CD73 |
600 |
2490 |
| 单抗 |
CHB026 |
Anti-NT5E / CD73 Reference Antibody (uliledlimab) |
NT5E / CD73 |
600 |
2490 |
| 单抗 |
CHA453 |
Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1) |
Orai1 |
600 |
2490 |
| 单抗 |
CHB029 |
Anti-OSMR Reference Antibody (vixarelimab) |
OSMR |
600 |
2490 |
| 单抗 |
CHB030 |
Anti-Osteopontin Reference Antibody (ASK8007) |
Osteopontin |
600 |
2490 |
| 单抗 |
CHA149 |
Anti-OX2R / CD200R1 Reference Antibody (Janssen patent anti-CD200R1) |
OX2R / CD200R1 |
600 |
2490 |
| 单抗 |
CHA961 |
Anti-oxLDL Reference Antibody (Okayama U. patent anti-oxLDL) |
oxLDL |
600 |
2490 |
| 单抗 |
CHB033 |
Anti-PAC1 Reference Antibody (zelminemab) |
PAC1 |
600 |
2490 |
| 单抗 |
CHA444 |
Anti-PACAP38 Reference Antibody (Lilly patent anti-PACAP) |
PACAP38 |
600 |
2490 |
| 单抗 |
CHA560 |
Anti-PAR2 Reference Antibody (PAR650097) |
PAR2 |
600 |
2490 |
| 单抗 |
CHB035 |
Anti-PAR2 Reference Antibody (Amgen patent anti-PAR-2) |
PAR2 |
600 |
2490 |
| 单抗 |
CHB057 |
Anti-PAR2 Reference Antibody (Regeneron patent anti-PAR-2) |
PAR2 |
600 |
2490 |
| 单抗 |
CHA316 |
Anti-PCSK9 Reference Antibody (alirocumab) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHA636 |
Anti-PCSK9 Reference Antibody (bococizumab) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHA637 |
Anti-PCSK9 Reference Antibody (Boehringer anti-PCSK9) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHA736 |
Anti-PCSK9 Reference Antibody (ebronucimab) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHA762 |
Anti-PCSK9 Reference Antibody (evolocumab) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHA796 |
Anti-PCSK9 Reference Antibody (frovocimab) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHA871 |
Anti-PCSK9 Reference Antibody (lodelcizumab) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHA981 |
Anti-PCSK9 Reference Antibody (ongericimab) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHB043 |
Anti-PCSK9 Reference Antibody (Merck patent anti-PCSK9) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHB044 |
Anti-PCSK9 Reference Antibody (ralpancizumab) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHB046 |
Anti-PCSK9 Reference Antibody (RG7652) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHB047 |
Anti-PCSK9 Reference Antibody (Schering patent anti-PCSK9) |
PCSK9 |
600 |
2490 |
| 单抗 |
CHA076 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (spartalizumab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHA077 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (camrelizumab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHA078 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (pembrolizumab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHA079 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (nivolumab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHA722 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (dostarlimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHA766 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (finotonlimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHA806 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (geptanolimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHA854 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (iparomlimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHA928 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (nofazinlimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB039 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (prolgolimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB049 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (balstilimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB050 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (budigalimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB052 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (cetrelimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB054 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (ezabenlimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB058 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (penpulimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB060 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (pimivalimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB061 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (retifanlimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB062 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (sasanlimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB063 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (serplulimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB064 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (sintilimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB065 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (tislelizumab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB066 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (UCB patent anti-PD-1) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB067 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (zimberelimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHB146 |
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (toripalimab) |
PDCD1 / PD-1 / CD279 |
600 |
2490 |
| 单抗 |
CHA080 |
Anti-PDGFB Reference Antibody (MOR-8457) |
PDGFB |
600 |
2490 |
| 单抗 |
CHA317 |
Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics patent anti-PDGF-C) |
PDGFC / VEGFE |
600 |
2490 |
| 单抗 |
CHA319 |
Anti-PDGFRA / CD140a Reference Antibody (olaratumab) |
PDGFRA / CD140a |
600 |
2490 |
| 单抗 |
CHA320 |
Anti-PDGFRB / CD140b Reference Antibody (rinucumab) |
PDGFRB / CD140b |
600 |
2490 |
| 单抗 |
CHB071 |
Anti-PDGFRB / CD140b Reference Antibody (IMC-2C5) |
PDGFRB / CD140b |
600 |
2490 |
| 单抗 |
CHA322 |
Anti-PGLYRP1 / PGRP-S Reference Antibody (Novo Nordisk patent anti-PGLYRP1) |
PGLYRP1 / PGRP-S |
600 |
2490 |
| 单抗 |
CHB074 |
Anti-Phosphatidylserine Reference Antibody (bavituximab) |
Phosphatidylserine |
600 |
2490 |
| 单抗 |
CHA411 |
Anti-Phosphorylcholine Reference Antibody (ATH3G10) |
Phosphorylcholine |
600 |
2490 |
| 单抗 |
CHA323 |
Anti-PLA2G1B Reference Antibody (Diaccurate patent anti-sPLA2-GIB) |
PLA2G1B |
600 |
2490 |
| 单抗 |
CHA085 |
Anti-PMEL Reference Antibody (Genentech anti-PMEL17) |
PMEL |
600 |
2490 |
| 单抗 |
CHA086 |
Anti-PMEL Reference Antibody (Novartis patent anti-PMEL17) |
PMEL |
600 |
2490 |
| 单抗 |
CHA463 |
Anti-Polyubiquitin Reference Antibody (Genentech patent anti-Polyubiquitin) |
Polyubiquitin |
600 |
2490 |
| 单抗 |
CHA325 |
Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) |
PRAME |
600 |
2490 |
| 单抗 |
CHA521 |
Anti-PRLR / Prolactin Receptor Reference Antibody (rolinsatamab) |
PRLR / Prolactin Receptor |
600 |
2490 |
| 单抗 |
CHB077 |
Anti-PRLR / Prolactin Receptor Reference Antibody (BAY 1158061) |
PRLR / Prolactin Receptor |
600 |
2490 |
| 单抗 |
CHA145 |
Anti-PROM1 / CD133 Reference Antibody (Forerunner patent anti-Prominin-1) |
PROM1 / CD133 |
600 |
2490 |
| 单抗 |
CHA087 |
Anti-P-Selectin / CD62p Reference Antibody (inclacumab) |
P-Selectin / CD62p |
600 |
2490 |
| 单抗 |
CHA088 |
Anti-P-Selectin / CD62p Reference Antibody (crizanlizumab) |
P-Selectin / CD62p |
600 |
2490 |
| 单抗 |
CHA089 |
Anti-PSGL1 / CD162 Reference Antibody (neihulizumab) |
PSGL1 / CD162 |
600 |
2490 |
| 单抗 |
CHA499 |
Anti-PTGFRN / CD315 Reference Antibody (AG02-ADC) |
PTGFRN / CD315 |
600 |
2490 |
| 单抗 |
CHA667 |
Anti-PTK7 / CCK4 Reference Antibody (cofetuzumab) |
PTK7 / CCK4 |
600 |
2490 |
| 单抗 |
CHA425 |
Anti-PTPRC / CD45 Reference Antibody (apamistamab) |
PTPRC / CD45 |
600 |
2490 |
| 单抗 |
CHA929 |
Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45) |
PTPRC / CD45 |
600 |
2490 |
| 单抗 |
CHB350 |
Anti-PVR / CD155 Reference Antibody (Ntx1088) |
PVR / CD155 |
600 |
2490 |
| 单抗 |
CHA327 |
Anti-PVRIG Reference Antibody (GSK4381562) |
PVRIG |
600 |
2490 |
| 单抗 |
CHA328 |
Anti-PVRIG Reference Antibody (COM701) |
PVRIG |
600 |
2490 |
| 单抗 |
CVA003 |
Anti-Rabies virus GP Reference Antibody (foravirumab) |
Rabies virus GP |
600 |
2490 |
| 单抗 |
CVA004 |
Anti-Rabies virus GP Reference Antibody (rafivirumab) |
Rabies virus GP |
600 |
2490 |
| 单抗 |
CHB084 |
Anti-RAMP3 Reference Antibody (Medella patent anti-RAMP-3) |
RAMP3 |
600 |
2490 |
| 单抗 |
CHA472 |
Anti-RG1 Reference Antibody (19G9) |
RG1 |
600 |
2490 |
| 单抗 |
CHA091 |
Anti-RGMA Reference Antibody (elezanumab) |
RGMA |
600 |
2490 |
| 单抗 |
CHA446 |
Anti-RGMC / HFE2 Reference Antibody (DISC-0974) |
RGMC / HFE2 |
600 |
2490 |
| 单抗 |
CHB081 |
Anti-RHD / CD240d Reference Antibody (roledumab) |
RHD / CD240d |
600 |
2490 |
| 单抗 |
CHB085 |
Anti-RHD / CD240d Reference Antibody (LFB Anti-RhD) |
RHD / CD240d |
600 |
2490 |
| 单抗 |
CHA370 |
Anti-ROBO1 Reference Antibody (Asclepius Technology patent anti-Robo1 CAR) |
ROBO1 |
600 |
2490 |
| 单抗 |
CHA092 |
Anti-ROR1 Reference Antibody (zilovertamab) |
ROR1 |
600 |
2490 |
| 单抗 |
CHB342 |
Anti-ROR2 Reference Antibody (Ozuriftamab) |
ROR2 |
600 |
2490 |
| 单抗 |
CHA332 |
Anti-RSPO1 Reference Antibody (Oncomed patent anti-RSPO1) |
RSPO1 |
600 |
2490 |
| 单抗 |
CHA333 |
Anti-RSPO3 Reference Antibody (rosmantuzumab) |
RSPO3 |
600 |
2490 |
| 单抗 |
CVA005 |
Anti-RSV-F Reference Antibody (motavizumab) |
RSV-F |
600 |
2490 |
| 单抗 |
CVA006 |
Anti-RSV-F Reference Antibody (palivizumab) |
RSV-F |
600 |
2490 |
| 单抗 |
CHA311 |
Anti-RTN4 / NOGO Reference Antibody (ozanezumab) |
RTN4 / NOGO |
600 |
2490 |
| 单抗 |
CHB088 |
Anti-RTN4 / NOGO Reference Antibody (atinumab) |
RTN4 / NOGO |
600 |
2490 |
| 单抗 |
CHB090 |
Anti-RTN4 / NOGO Reference Antibody (NG-101) |
RTN4 / NOGO |
600 |
2490 |
| 单抗 |
CHB091 |
Anti-S100A4 Reference Antibody (LK-1) |
S100A4 |
600 |
2490 |
| 单抗 |
CHA141 |
Anti-SCFR / c-Kit / CD117 Reference Antibody (LOP628) |
SCFR / c-Kit / CD117 |
600 |
2490 |
| 单抗 |
CHA530 |
Anti-SCFR / c-Kit / CD117 Reference Antibody (CDX-0158) |
SCFR / c-Kit / CD117 |
600 |
2490 |
| 单抗 |
CHA567 |
Anti-SCN11a / Nav1.9 Reference Antibody (Wuhan U. patent anti-Nav1.9) |
SCN11a / Nav1.9 |
600 |
2490 |
| 单抗 |
CHA464 |
Anti-SCN9a / Nav1.7 Reference Antibody (Duke anti-NAv1.7) |
SCN9a / Nav1.7 |
600 |
2490 |
| 单抗 |
CHA336 |
Anti-SEMA4D / CD100 Reference Antibody (pepinemab) |
SEMA4D / CD100 |
600 |
2490 |
| 单抗 |
CHA454 |
Anti-SERPINE1 Reference Antibody (Sanofi patent anti-PAI-1) |
SERPINE1 |
600 |
2490 |
| 单抗 |
CHA117 |
Anti-Serum Amyloid P / SAP Reference Antibody (dezamizumab) |
Serum Amyloid P / SAP |
600 |
2490 |
| 单抗 |
CHB357 |
Anti-SEZ6 Reference Antibody (Abbv-011) |
SEZ6 |
600 |
2490 |
| 单抗 |
COA003 |
Anti-Shiga toxin (E.coli) Reference Antibody (pritoxaximab) |
Shiga toxin (E.coli) |
600 |
2490 |
| 单抗 |
COA004 |
Anti-Shiga toxin (E.coli) Reference Antibody (setoxaximab) |
Shiga toxin (E.coli) |
600 |
2490 |
| 单抗 |
CHA093 |
Anti-Siglec-15 / CD33L3 Reference Antibody (NC318) |
Siglec-15 / CD33L3 |
600 |
2490 |
| 单抗 |
CHB093 |
Anti-Siglec-15 / CD33L3 Reference Antibody (AB-25E9) |
Siglec-15 / CD33L3 |
600 |
2490 |
| 单抗 |
CHB094 |
Anti-Siglec-15 / CD33L3 Reference Antibody (Medimmune patent anti-Siglec-15) |
Siglec-15 / CD33L3 |
600 |
2490 |
| 单抗 |
CHB096 |
Anti-Siglec-2 / CD22 Reference Antibody (epratuzumab) |
Siglec-2 / CD22 |
600 |
2490 |
| 单抗 |
CHB097 |
Anti-Siglec-2 / CD22 Reference Antibody (NCI m971) |
Siglec-2 / CD22 |
600 |
2490 |
| 单抗 |
CHB098 |
Anti-Siglec-2 / CD22 Reference Antibody (NCI m972) |
Siglec-2 / CD22 |
600 |
2490 |
| 单抗 |
CHB099 |
Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab) |
Siglec-2 / CD22 |
600 |
2490 |
| 单抗 |
CHA022 |
Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab) |
Siglec-3 / CD33 |
600 |
2490 |
| 单抗 |
CHA577 |
Anti-Siglec-3 / CD33 Reference Antibody (lintuzumAb) |
Siglec-3 / CD33 |
600 |
2490 |
| 单抗 |
CHB100 |
Anti-Siglec-3 / CD33 Reference Antibody (IMGN779) |
Siglec-3 / CD33 |
600 |
2490 |
| 单抗 |
CHB341 |
Anti-Siglec-3 / CD33 Reference Antibody (Gemtuzumab) |
Siglec-3 / CD33 |
600 |
2490 |
| 单抗 |
CHA293 |
Anti-Siglec-4a / MAG Reference Antibody (refanezumab) |
Siglec-4a / MAG |
600 |
2490 |
| 单抗 |
CHA094 |
Anti-Siglec-8 Reference Antibody (lirentelimab) |
Siglec-8 |
600 |
2490 |
| 单抗 |
CHA337 |
Anti-SIRPa / CD172a Reference Antibody (Hospital for Sick Children patent anti-SIRPA) |
SIRPa / CD172a |
600 |
2490 |
| 单抗 |
CHB228 |
Anti-SIRPa / CD172a Reference Antibody (BI 765063) |
SIRPa / CD172a |
600 |
2490 |
| 单抗 |
CHA338 |
Anti-SIRPg / CD172g Reference Antibody (KWAR23) |
SIRPg / CD172g |
600 |
2490 |
| 单抗 |
CHA095 |
Anti-SLAMF7 / CS1 Reference Antibody (elotuzumab) |
SLAMF7 / CS1 |
600 |
2490 |
| 单抗 |
CHB102 |
Anti-SLAMF7 / CS1 Reference Antibody (azintuxizumAb) |
SLAMF7 / CS1 |
600 |
2490 |
| 单抗 |
CHB103 |
Anti-SLAMF7 / CS1 Reference Antibody (PDL241) |
SLAMF7 / CS1 |
600 |
2490 |
| 单抗 |
CHA372 |
Anti-SLC1A5 / ASCT2 Reference Antibody (idactamab) |
SLC1A5 / AAAT / ASCT2 / M7V1 / RDR / RDRC |
600 |
2490 |
| 单抗 |
CHB104 |
Anti-SLC2A8 Reference Antibody (VB1-050) |
SLC2A8 |
600 |
2490 |
| 单抗 |
CHB351 |
Anti-CD98 Reference Antibody (Ign523) |
SLC3A2 / CD98 |
600 |
2490 |
| 单抗 |
CHA212 |
Anti-SLC40A1 Reference Antibody (LY2928057) |
SLC40A1 |
600 |
2490 |
| 单抗 |
CHA213 |
Anti-SLC40A1 Reference Antibody (Amgen patent anti-Ferroportin) |
SLC40A1 |
600 |
2490 |
| 单抗 |
CHA525 |
Anti-SLC44A4 Reference Antibody (ASG-5ME) |
SLC44A4 |
600 |
2490 |
| 单抗 |
CHB354 |
Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) |
SLC7A11 / XCT |
600 |
2490 |
| 单抗 |
CHA526 |
Anti-SLITRK6 Reference Antibody (sirtratumab) |
SLITRK6 |
600 |
2490 |
| 单抗 |
CHA866 |
Anti-Sortilin / SORT1 Reference Antibody (latozinemab) |
Sortilin / SORT1 |
600 |
2490 |
| 单抗 |
CHA334 |
Anti-SOST / Sclerostin Reference Antibody (setrusumab) |
SOST / Sclerostin |
600 |
2490 |
| 单抗 |
CHA335 |
Anti-SOST / Sclerostin Reference Antibody (romosozumab) |
SOST / Sclerostin |
600 |
2490 |
| 单抗 |
CHA635 |
Anti-SOST / Sclerostin Reference Antibody (blosozumab) |
SOST / Sclerostin |
600 |
2490 |
| 单抗 |
CHA763 |
Anti-Sphingosine-1-phosphate Reference Antibody (Expression DD patent anti-SIP) |
Sphingosine-1-phosphate |
600 |
2490 |
| 单抗 |
CHB110 |
Anti-Sphingosine-1-phosphate Reference Antibody (sonepcizumab) |
Sphingosine-1-phosphate |
600 |
2490 |
| 单抗 |
CHB001-3 |
IgG1/Kappa Isotype Control |
Spike RBD |
600 |
2490 |
| 单抗 |
CHA341 |
Anti-STAB1 Reference Antibody (bexmarilimab) |
STAB1 |
600 |
2490 |
| 单抗 |
CHB175 |
Anti-STEAP1 Reference Antibody (vandortuzumAb) |
STEAP1 |
600 |
2490 |
| 单抗 |
CHA459 |
Anti-STOP1 Reference Antibody (Genentech patent anti-STOP-1) |
STOP1 |
600 |
2490 |
| 单抗 |
CHA343 |
Anti-Syndecan-1 / CD138 Reference Antibody (indatuximab) |
Syndecan-1 / CD138 |
600 |
2490 |
| 单抗 |
CHA447 |
Anti-TAT226 Reference Antibody (Genentech patent anti-TAT226) |
TAT226 |
600 |
2490 |
| 单抗 |
CHA344 |
Anti-Tau Reference Antibody (gosuranemab) |
Tau |
600 |
2490 |
| 单抗 |
CHA345 |
Anti-Tau Reference Antibody (semorinemab) |
Tau |
600 |
2490 |
| 单抗 |
CHB113 |
Anti-Tau Reference Antibody (bepranemab) |
Tau |
600 |
2490 |
| 单抗 |
CHB133 |
Anti-Tau Reference Antibody (tilavonemab) |
Tau |
600 |
2490 |
| 单抗 |
CHB191 |
Anti-Tau Reference Antibody (zagotenemab) |
Tau |
600 |
2490 |
| 单抗 |
CHB693 |
Anti-Tau Reference Antibody (pT217,human IgG1) |
Tau |
600 |
2490 |
| 单抗 |
CHB694 |
Anti-Tau Reference Antibody (pT217,mouse IgG1) |
Tau |
600 |
2490 |
| 单抗 |
CHB695 |
Anti-Tau Reference Antibody (pT217,rabbit IgG1) |
Tau |
600 |
2490 |
| 单抗 |
CHB696 |
Anti-Tau Reference Antibody (A054) |
Tau |
600 |
2490 |
| 单抗 |
CHB697 |
Anti-Tau Reference Antibody (A103) |
Tau |
600 |
2490 |
| 单抗 |
CHB698 |
Anti-Tau Reference Antibody (A105) |
Tau |
600 |
2490 |
| 单抗 |
CHB699 |
Anti-Tau Reference Antibody (A080) |
Tau |
600 |
2490 |
| 单抗 |
CHB700 |
Anti-Tau Reference Antibody (A119) |
Tau |
600 |
2490 |
| 单抗 |
CHB701 |
Anti-Tau Reference Antibody (A155) |
Tau |
600 |
2490 |
| 单抗 |
CHB117 |
Anti-TBFbR2 Reference Antibody (LY3022859) |
TBFbR2 |
600 |
2490 |
| 单抗 |
CHB118 |
Anti-TCR Reference Antibody (NKTT320) |
TCR |
600 |
2490 |
| 单抗 |
CHB139 |
Anti-TCR Reference Antibody (TOL101) |
TCR |
600 |
2490 |
| 单抗 |
CHA495 |
Anti-TEM1 / Endosialin / CD248 Reference Antibody (ontuxizumab) |
TEM1 / Endosialin / CD248 |
600 |
2490 |
| 单抗 |
CHA792 |
Anti-TEM7R / PLXDC2 Reference Antibody (Fox Chase patent anti-TEM7R) |
TEM7R / PLXDC2 |
600 |
2490 |
| 单抗 |
CHB122 |
Anti-Tenascin C Reference Antibody (tenatumomab) |
Tenascin C |
600 |
2490 |
| 单抗 |
CHA346 |
Anti-TF / Factor III / Tissue Factor / CD142 Reference Antibody (tisotumab) |
TF / Factor III / Tissue Factor / CD142 |
600 |
2490 |
| 单抗 |
CHB134 |
Anti-TF / Factor III / Tissue Factor / CD142 Reference Antibody (Chugai patent anti-TF) |
TF / Factor III / Tissue Factor / CD142 |
600 |
2490 |
| 单抗 |
CHB137 |
Anti-TF / Factor III / Tissue Factor / CD142 Reference Antibody (TNX-832) |
TF / Factor III / Tissue Factor / CD142 |
600 |
2490 |
| 单抗 |
CHA615 |
Anti-TFPI Reference Antibody (befovacimab) |
TFPI |
600 |
2490 |
| 单抗 |
CHA669 |
Anti-TFPI Reference Antibody (concizumab) |
TFPI |
600 |
2490 |
| 单抗 |
CHB124 |
Anti-TFPI Reference Antibody (marstacimab) |
TFPI |
600 |
2490 |
| 单抗 |
CHB347 |
Anti-TfR Reference Antibody (Jr-141) |
TfR |
600 |
2490 |
| 单抗 |
CHA347 |
Anti-TGFb1 Reference Antibody (SRK181) |
TGFb1 |
600 |
2490 |
| 单抗 |
CHA348 |
Anti-TGFb1 Reference Antibody (M7824) |
TGFb1 |
600 |
2490 |
| 单抗 |
CHA793 |
Anti-TGFb1 Reference Antibody (fresolimumab) |
TGFb1 |
600 |
2490 |
| 单抗 |
CHB126 |
Anti-TGFb1 Reference Antibody (NIS793) |
TGFb1 |
600 |
2490 |
| 单抗 |
CHB215 |
Anti-TGFb1 Reference Antibody (Genzyme patent anti-TGF-β) |
TGFb1 |
600 |
2490 |
| 单抗 |
CHB127 |
Anti-TGM2 / Transglutaminase 2 Reference Antibody (zampilimab) |
TGM2 / Transglutaminase 2 |
600 |
2490 |
| 单抗 |
CHA461 |
Anti-TIE2 / CD202b Reference Antibody (Regeneron patent anti-TIE-2) |
TIE2 / CD202b |
600 |
2490 |
| 单抗 |
CHA096 |
Anti-TIGIT Reference Antibody (tiragolumab) |
TIGIT / VSIG9 / VSTM3 |
600 |
2490 |
| 单抗 |
CHA719 |
Anti-TIGIT Reference Antibody (domvanalimab) |
TIGIT / VSIG9 / VSTM3 |
600 |
2490 |
| 单抗 |
CHA952 |
Anti-TIGIT Reference Antibody (ociperlimab) |
TIGIT / VSIG9 / VSTM3 |
600 |
2490 |
| 单抗 |
CHB129 |
Anti-TIGIT Reference Antibody (etigilimab) |
TIGIT / VSIG9 / VSTM3 |
600 |
2490 |
| 单抗 |
CHB182 |
Anti-TIGIT Reference Antibody (vibostolimab) |
TIGIT / VSIG9 / VSTM3 |
600 |
2490 |
| 单抗 |
CHA349 |
Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (sabatolimab) |
TIM-3 / HAVCR2 / CD366 |
600 |
2490 |
| 单抗 |
CHA666 |
Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (cobolimab) |
TIM-3 / HAVCR2 / CD366 |
600 |
2490 |
| 单抗 |
CHB603 |
Anti-TL1A Reference Antibody (PR200，1D1) |
TL1A |
600 |
2490 |
| 单抗 |
CHB652 |
Anti-TL1A Reference Antibody (PR200，5C3D11) |
TL1A |
600 |
2490 |
| 单抗 |
CHB653 |
Anti-TL1A Reference Antibody (PF-06480605) |
TL1A |
600 |
2490 |
| 单抗 |
CHA350 |
Anti-TLR2 / CD282 Reference Antibody (tomaralimab) |
TLR2 / CD282 |
600 |
2490 |
| 单抗 |
CHA665 |
Anti-TLR3 / CD283 Reference Antibody (CNTO5429) |
TLR3 / CD283 |
600 |
2490 |
| 单抗 |
CHA569 |
Anti-TLR7 Reference Antibody (U.Tokyo patent anti-TLR7) |
TLR7 |
600 |
2490 |
| 单抗 |
CHB343 |
Anti-TM4SF1 Reference Antibody (Beth Israel Patent Anti-TM4SF1) |
TM4SF1 / T4S1 / M3S1 / TAAL6 |
600 |
2490 |
| 单抗 |
CHA502 |
Anti-TMEFF1 / Tomoregulin-1 Reference Antibody (Bluefin patent anti-TMEFF1) |
TMEFF1 / Tomoregulin-1 |
600 |
2490 |
| 单抗 |
CHA460 |
Anti-TMEFF2 Reference Antibody (Janssen patent anti-TMEFF2) |
TMEFF2 |
600 |
2490 |
| 单抗 |
CHA448 |
Anti-TMPRSS2 Reference Antibody (Regeneron patent anti-TMPRSS2 ) |
TMPRSS2 |
600 |
2490 |
| 单抗 |
CHA352 |
Anti-TNFRSF10A / TRAILR1 / CD261 Reference Antibody ( mapatumumab) |
TNFRSF10A / TRAILR1 / CD261 |
600 |
2490 |
| 单抗 |
CHA039 |
Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (conatumumab) |
TNFRSF10B / TRAILR2 / CD262 |
600 |
2490 |
| 单抗 |
CHA040 |
Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (tigatuzumab) |
TNFRSF10B / TRAILR2 / CD262 |
600 |
2490 |
| 单抗 |
CHA571 |
Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (drozitumab) |
TNFRSF10B / TRAILR2 / CD262 |
600 |
2490 |
| 单抗 |
CHB136 |
Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (tilogotamab) |
TNFRSF10B / TRAILR2 / CD262 |
600 |
2490 |
| 单抗 |
CHB138 |
Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (benufutamab) |
TNFRSF10B / TRAILR2 / CD262 |
600 |
2490 |
| 单抗 |
CHB140 |
Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (lexatumumab) |
TNFRSF10B / TRAILR2 / CD262 |
600 |
2490 |
| 单抗 |
CHA356 |
Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) |
TNFRSF12A / TWEAKR / CD266 |
600 |
2490 |
| 单抗 |
CHA377 |
Anti-TNFRSF13C / BAFFR / CD268 Reference Antibody (ianalumab) |
TNFRSF13C / BAFFR / CD268 |
600 |
2490 |
| 单抗 |
CHA154 |
Anti-TNFRSF17 / BCMA / CD269 Reference Antibody (belantamab) |
TNFRSF17 / BCMA / CD269 |
600 |
2490 |
| 单抗 |
CHA230 |
Anti-TNFRSF18 / GITR / CD357 Reference Antibody (ragifilimab) |
TNFRSF18 / GITR / CD357 |
600 |
2490 |
| 单抗 |
CHA863 |
Anti-TNFRSF18 / GITR / CD357 Reference Antibody (Korea Natl.Cancer Ctr. patent anti-GITR) |
TNFRSF18 / GITR / CD357 |
600 |
2490 |
| 单抗 |
CHA201 |
Anti-TNFRSF21 / DR6 / CD358 Reference Antibody (Abbvie patent anti-TNFRSF21) |
TNFRSF21 / DR6 / CD358 |
600 |
2490 |
| 单抗 |
CHA314 |
Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (tavolixizumab) |
TNFRSF4 / OX40 / CD134 |
600 |
2490 |
| 单抗 |
CHA692 |
Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (cudarolimab) |
TNFRSF4 / OX40 / CD134 |
600 |
2490 |
| 单抗 |
CHA857 |
Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (ivuxolimab) |
TNFRSF4 / OX40 / CD134 |
600 |
2490 |
| 单抗 |
CHB069 |
Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (revdofilimab) |
TNFRSF4 / OX40 / CD134 |
600 |
2490 |
| 单抗 |
CHB121 |
Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (telazorlimab) |
TNFRSF4 / OX40 / CD134 |
600 |
2490 |
| 单抗 |
CHB147 |
Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (BMS-986178) |
TNFRSF4 / OX40 / CD134 |
600 |
2490 |
| 单抗 |
CHB189 |
Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (vonlerizumab) |
TNFRSF4 / OX40 / CD134 |
600 |
2490 |
| 单抗 |
CHA160 |
Anti-TNFRSF5 / CD40 Reference Antibody (bleselumab) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHA161 |
Anti-TNFRSF5 / CD40 Reference Antibody (sotigalimab) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHA162 |
Anti-TNFRSF5 / CD40 Reference Antibody (dacetuzumab) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHA574 |
Anti-TNFRSF5 / CD40 Reference Antibody (selicrelumab) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHA741 |
Anti-TNFRSF5 / CD40 Reference Antibody (Emory U. anti-CD40) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHA808 |
Anti-TNFRSF5 / CD40 Reference Antibody (giloralimab) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHB156 |
Anti-TNFRSF5 / CD40 Reference Antibody (iscalimab) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHB157 |
Anti-TNFRSF5 / CD40 Reference Antibody (lucatumumab) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHB158 |
Anti-TNFRSF5 / CD40 Reference Antibody (mitazalimab) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHB159 |
Anti-TNFRSF5 / CD40 Reference Antibody (ravagalimab) |
TNFRSF5 / CD40 |
600 |
2490 |
| 单抗 |
CHA019 |
Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) |
TNFRSF7 / CD27 |
600 |
2490 |
| 单抗 |
CHB002 |
Anti-TNFRSF7 / CD27 Reference Antibody (Organon patent anti-CD27) |
TNFRSF7 / CD27 |
600 |
2490 |
| 单抗 |
CHA021 |
Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) |
TNFRSF8 / CD30 |
600 |
2490 |
| 单抗 |
CHA102 |
Anti-TNFRSF9 / 4-1BB / CD137 Reference Antibody (utomilumab) |
TNFRSF9 / 4-1BB / CD137 |
600 |
2490 |
| 单抗 |
CHA103 |
Anti-TNFRSF9 / 4-1BB / CD137 Reference Antibody (urelumab) |
TNFRSF9 / 4-1BB / CD137 |
600 |
2490 |
| 单抗 |
CHB161 |
Anti-TNFSF1 / TNFb/ LT alpha Reference Antibody (pateclizumab) |
TNFSF1 / TNFb/ LT alpha |
600 |
2490 |
| 单抗 |
CHA330 |
Anti-TNFSF11 / RANKL / CD254 Reference Antibody (denosumab) |
TNFSF11 / RANKL / CD254 |
600 |
2490 |
| 单抗 |
CHB070 |
Anti-TNFSF12 / TWEAK Reference Antibody (RO5458640) |
TNFSF12 / TWEAK |
600 |
2490 |
| 单抗 |
CHA118 |
Anti-TNFSF13 / APRIL / CD256 Reference Antibody (BION-1301) |
TNFSF13 / APRIL / CD256 |
600 |
2490 |
| 单抗 |
CHB165 |
Anti-TNFSF13 / APRIL / CD256 Reference Antibody (sibeprenlimab) |
TNFSF13 / APRIL / CD256 |
600 |
2490 |
| 单抗 |
CHA123 |
Anti-TNFSF13B / BAFF / CD257 Reference Antibody (belimumab) |
TNFSF13B / BAFF / CD257 |
600 |
2490 |
| 单抗 |
CHB167 |
Anti-TNFSF13B / BAFF / CD257 Reference Antibody (tabalumab) |
TNFSF13B / BAFF / CD257 |
600 |
2490 |
| 单抗 |
CHB168 |
Anti-TNFSF14 / LIGHT / CD258 Reference Antibody (SAR252067) |
TNFSF14 / LIGHT / CD258 |
600 |
2490 |
| 单抗 |
CHA097 |
Anti-TNFSF2 / TNFa Reference Antibody (adalimumab) |
TNFSF2 / TNFa |
600 |
2490 |
| 单抗 |
CHA098 |
Anti-TNFSF2 / TNFa Reference Antibody (infliximab) |
TNFSF2 / TNFa |
600 |
2490 |
| 单抗 |
CHA656 |
Anti-TNFSF2 / TNFa Reference Antibody (certolizumAb) |
TNFSF2 / TNFa |
600 |
2490 |
| 单抗 |
CHA754 |
Anti-TNFSF2 / TNFa Reference Antibody (Epitomics patent anti-TNFα) |
TNFSF2 / TNFa |
600 |
2490 |
| 单抗 |
CHA819 |
Anti-TNFSF2 / TNFa Reference Antibody (golimumab) |
TNFSF2 / TNFa |
600 |
2490 |
| 单抗 |
CHB169 |
Anti-TNFSF2 / TNFa Reference Antibody (CDP571) |
TNFSF2 / TNFa |
600 |
2490 |
| 单抗 |
CHB171 |
Anti-TNFSF2 / TNFa Reference Antibody (CMAB008) |
TNFSF2 / TNFa |
600 |
2490 |
| 单抗 |
CHB172 |
Anti-TNFSF2 / TNFa Reference Antibody (ESBA 105) |
TNFSF2 / TNFa |
600 |
2490 |
| 单抗 |
CHB173 |
Anti-TNFSF2 / TNFa Reference Antibody (hMAK195) |
TNFSF2 / TNFa |
600 |
2490 |
| 单抗 |
CHA315 |
Anti-TNFSF4 / OX40L / CD252 Reference Antibody (oxelumab) |
TNFSF4 / OX40L / CD252 |
600 |
2490 |
| 单抗 |
CHA579 |
Anti-TNFSF4 / OX40L / CD252 Reference Antibody (amlitelimab) |
TNFSF4 / OX40L / CD252 |
600 |
2490 |
| 单抗 |
CHA696 |
Anti-TNFSF5 / CD40L / CD154 Reference Antibody (dapirolizumab) |
TNFSF5 / CD40L / CD154 |
600 |
2490 |
| 单抗 |
CHB180 |
Anti-TNFSF5 / CD40L / CD154 Reference Antibody (ruplizumab) |
TNFSF5 / CD40L / CD154 |
600 |
2490 |
| 单抗 |
CHA027 |
Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) |
TNFSF7 / CD27L / CD70 |
600 |
2490 |
| 单抗 |
CHA529 |
Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) |
TNFSF7 / CD27L / CD70 |
600 |
2490 |
| 单抗 |
CHA104 |
Anti-TNFSF9 / 4-1BBL Reference Antibody (Abbvie patent anti-TNFSF9) |
TNFSF9 / 4-1BBL |
600 |
2490 |
| 单抗 |
CHA478 |
Anti-TPBG Reference Antibody (PF-06263507) |
TPBG |
600 |
2490 |
| 单抗 |
CHA908 |
Anti-TPBG Reference Antibody (naptumomAb) |
TPBG |
600 |
2490 |
| 单抗 |
CHB184 |
Anti-TPBG Reference Antibody (Wyeth patent anti-5T4) |
TPBG |
600 |
2490 |
| 单抗 |
CHB218 |
Anti-TPBG Reference Antibody (ASN004) |
TPBG |
600 |
2490 |
| 单抗 |
CHA433 |
Anti-TPSAB1 Reference Antibody (Genentech patent anti-Tryptase Beta 1) |
TPSAB1 |
600 |
2490 |
| 单抗 |
CHA565 |
Anti-TREM1 / CD354 Reference Antibody (PY159) |
TREM1 / CD354 |
600 |
2490 |
| 单抗 |
CHB356 |
Anti-TREM2 Reference Antibody (PY314) |
TREM2 |
600 |
2490 |
| 单抗 |
CHA354 |
Anti-TrkA / NTRK1 Reference Antibody (GBR 900) |
TrkA / NTRK1 |
600 |
2490 |
| 单抗 |
CHB185 |
Anti-TrkB / NTRK2 Reference Antibody (Rinat patent anti-TrkB) |
TrkB / NTRK2 |
600 |
2490 |
| 单抗 |
CHA355 |
Anti-TROP2 Reference Antibody (sacituzumab) |
TROP2 |
600 |
2490 |
| 单抗 |
CHA767 |
Anti-TRP1 / TYRP1 Reference Antibody (flanvotumab) |
TRP1 / TYRP1 |
600 |
2490 |
| 单抗 |
CHA548 |
Anti-TSHR Reference Antibody (K1-70) |
TSHR / LGR3 |
600 |
2490 |
| 单抗 |
CHB186 |
Anti-TSLP Reference Antibody (Schering patent anti-TSLP) |
TSLP |
600 |
2490 |
| 单抗 |
CHB216 |
Anti-TSLP Reference Antibody (tezepelumab) |
TSLP |
600 |
2490 |
| 单抗 |
CHA023 |
Anti-TSPAN26 / CD37 Reference Antibody (naratuximab) |
TSPAN26 / CD37 |
600 |
2490 |
| 单抗 |
CHA869 |
Anti-TSPAN26 / CD37 Reference Antibody (lilotomab) |
TSPAN26 / CD37 |
600 |
2490 |
| 单抗 |
CHB187 |
Anti-TSPAN26 / CD37 Reference Antibody (AGS67E) |
TSPAN26 / CD37 |
600 |
2490 |
| 单抗 |
CHA851 |
Anti-TSPAN8 Reference Antibody (INSERM patent anti-CO-029) |
TSPAN8 |
600 |
2490 |
| 单抗 |
CHA357 |
Anti-TYRO3 Reference Antibody (ELB031) |
TYRO3 |
600 |
2490 |
| 单抗 |
CHB190 |
Anti-VCAM1 / CD106 Reference Antibody (Hanwha patent anti-VCAM-1) |
VCAM1 / CD106 |
600 |
2490 |
| 单抗 |
CHA099 |
Anti-VEGF Reference Antibody (bevacizumab) |
VEGF |
600 |
2490 |
| 单抗 |
CHA715 |
Anti-VEGF Reference Antibody (Domantis patent anti-VEGF) |
VEGF |
600 |
2490 |
| 单抗 |
CHB193 |
Anti-VEGF Reference Antibody (ranibizumab) |
VEGF |
600 |
2490 |
| 单抗 |
CHB194 |
Anti-VEGF Reference Antibody (varisacumab) |
VEGF |
600 |
2490 |
| 单抗 |
CHA400 |
Anti-VEGFB Reference Antibody (CSL346) |
VEGFB |
600 |
2490 |
| 单抗 |
CHB195 |
Anti-VEGFC Reference Antibody (VGX100) |
VEGFC |
600 |
2490 |
| 单抗 |
CHA586 |
Anti-VEGFR1 / FLT1 Reference Antibody (Abbott patent anti-Flt1) |
VEGFR1 / FLT1 |
600 |
2490 |
| 单抗 |
CHA100 |
Anti-VEGFR2 / KDR / CD309 Reference Antibody (ramucirumab) |
VEGFR2 / KDR / CD309 |
600 |
2490 |
| 单抗 |
CHA840 |
Anti-VEGFR2 / KDR / CD309 Reference Antibody (Imclone 6.64) |
VEGFR2 / KDR / CD309 |
600 |
2490 |
| 单抗 |
CHA968 |
Anti-VEGFR2 / KDR / CD309 Reference Antibody (olinvacimab) |
VEGFR2 / KDR / CD309 |
600 |
2490 |
| 单抗 |
CHB196 |
Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) |
VEGFR2 / KDR / CD309 |
600 |
2490 |
| 单抗 |
CHB197 |
Anti-VEGFR2 / KDR / CD309 Reference Antibody (AT001) |
VEGFR2 / KDR / CD309 |
600 |
2490 |
| 单抗 |
CHB198 |
Anti-VEGFR2 / KDR / CD309 Reference Antibody (vulinacimab) |
VEGFR2 / KDR / CD309 |
600 |
2490 |
| 单抗 |
CHB199 |
Anti-VEGFR3 / FLT4 Reference Antibody (LY3022856) |
VEGFR3 / FLT4 |
600 |
2490 |
| 单抗 |
CHA430 |
Anti-vWF Reference Antibody (INSERM patent anti-vWF) |
vWF |
600 |
2490 |